
price data provid thomson reuter
number may add due round
initi coverag outperform us
share under-valued view base posit long-term outlook
compani differenti potenti best-in-class gene edit platform
base edit abl gener highli effici predict singl
base pair chang genom dna order correct genet diseas
manner beam base editor could theoret correct known point
mutat associ diseas genet mutat furthermor
base edit promis greater edit effici less collater dna damag
tradit gene edit platform zfn talen sinc
base edit gener double-strand break dsb requir donor
dna templat reli cellular homology-direct repair hdr short
believ base edit premier genom edit technolog therapeut
applic singl base pair chang desir specif a-t g-c
c-g t-a
method includ therapeut area hematolog sickl cell diseas
beta-thalassemia oncolog ex vivo multiplex edit creat next-
gener car-t aml liver diseas antitrypsin defici
glycogen storag disord type ocular disord stargardt
diseas deliveri method includ electropor hematolog oncolog
non-vir lnp deliveri liver diseas viral aav deliveri ocular
disord notabl genet diseas program base edit could potenti
allow function cure follow one-tim treatment beam oncolog
program believ abil effici achiev multiplex edit without
diminish cell fit make base edit ideal develop competit
upmultipl preclin data readout scientif medic
confer compani initi wave ind file expect begin
anticip share continu appreci compani demonstr
addit preclin vivo proof-of-concept next month see
initi ind accept beam deliveri modal signific catalyst
share posit read-through addit product
candid largest valuat compon compani candid
scd aatd initi patient data indic would key de-risk
valu inflect point share view born
gener gene therapy-focus compani past
initi coverag outperform rate price target pt
deriv sum-of-part valuat compani seven preclin
diseas program pediatr t-all aml scd tdbt aatd
stargardt diseas program appli multipl estim us/eu
sale less high single-digit royalti per program valuat year
discount back risk-adjust discount rate
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
preclinical-stag biotech advanc novel gene edit platform base edit gener
precis predict singl base pair chang genom dna order correct genet diseas believ
platform offer potenti greater specif edit effici tradit gene edit platform
zfn talen consequ see wide rang therapeut applic includ direct
correct pathogen point mutat gene silenc activ multiplex edit without loss cell
viabil current focus therapeut area hematolog oncolog allogen car-t liver
diseas ocular disord expect report preclin data platform
initi ind begin short hold posit long-term view share given best-in-class
gene edit platform attract diseas target consider option lucr busi develop
advantag compet
clinic valid ex
vivo vivo edit
product candid progress
target prove clinic
signific expect
base edit show advantag
compet platform
superior base edit
product candid prove
preclin updat across base edit platform
multipl scientif medic meet asgct may
multipl us/eu sale
lead preclin diseas program t-all aml scd
tdbt aatd discount rate
cambridg ma-bas
gene edit candid novel base edit
platform rare genet diseas cancer
continu demonstr base edit capabl
differenti
progress ind file
posit given earli preclin demonstr base
creat bluematrix
tabl content
compani platform overview
valuat outlook
advantag base edit
ration applic base edit
specif consider base edit
deliveri base editor
futur develop base editor
sickl cell diseas -thalassemia
beam solut edit approach hemoglobinopathi
ex vivo car-t candid pediatr t-all aml
beam solut multiplex base edit allogen cell therapi
non-vir base edit deliveri liver diseas
viral deliveri ocular disord
collabor licens agreement intellectu properti manufactur
research collabor agreement
prime edit detail search-and-replac genom edit without double-strand break
sickl cell diseas beta-thalassemia
market opportun valuat
market opportun sickl cell diseas beta-thalassemia
market opportun pediatr t-all aml
tabl figur
figur product site-specif nuclease-bas gene edit
figur non-homolog end join nhej homology-direct repair hdr follow
double-strand break dsb gene edit
figur schemat zinc-fing nucleas
figur schemat talen
figur schemat megat
figur schemat
figur method deliv genome-edit tool
figur mode nucleas deliveri
figur base edit offer pencil-lik precis rel genom edit tool
figur cytosin adenin base editor
figur technic detail cbe base edit
figur technic detail abe base edit
figur high precis effici correct base edit vs tradit gene
figur distribut human pathogen variant includ point mutat
figur preclin valid ex electropor lnp deliveri
figur schemat split-intein base editor
figur system inject editor result cytosin adenin base edit
heart muscl liver
figur aav-medi cytosin adenin base edit
figur balanc on-target edit greatli decreas edit
figur rna edit repair
figur protein domain structur nucleas
figur comp tabl lead gene edit platform
figur etiolog sickl cell diseas
figur fetal-to-adult hemoglobin switch normal develop sickl cell diseas
figur base edit re-creat hereditari persist fetal hemoglobin hpfh
figur retent edit hematopoiet stem cell
figur singl base chang abe convert makassar variant primari
fibroblast deriv scd patient
figur comparison autolog allogen car-t cell
figur manufactur allogen car-t cell
figur simultan base edit donor cell car-t
figur detect transloc triple-edit cell cbe compar
figur cell yield rel electropor ep control
figur ifni releas post co-cultur
figur potenti gene target amen multiplex base edit
figur aatd increas effici across abe variant month evolut
figur abe correct preval disease-caus mutat
figur stargardt diseas abe correct mutat cell
figur stargardt abe edit surrog base split aav deliveri retin cell
figur overview prime edit
figur select publicly-trad gene edit gene therapi landscap
figur preclin edit data hemoglobinopathi candid
figur initi ph data fetal hemoglobin g/dl time evalu patient
figur competit landscap gene cell therapi sickl cell diseas
figur competit landscap small molecul biolog sickl cell diseas
figur competit landscap gene cell therapi beta-thalassemia
figur competit landscap small molecul biolog forbeta-thalassemia
figur ww brand hemoglobinopathi market expect grow annual
figur fda-approv therapi hemoglobinopathi
compani platform overview
therapeut preclinical-stag biotechnolog compani develop
novel approach gene edit call base edit gener precis predict singl
base pair chang genom dnaus guiderna-direct deaminas activityin order
correct human genet diseas manner beam adenin cytosin base editor
enact a-tg-c c-gt-a correct respect current could potenti address
known point mutat associ diseas genet mutat
furthermor base edit offer potenti greater specif edit effici without
potenti dna damag tradit gene edit platform zfn talen
base edit gener double-strand break dsb requir donor dna templat
reli cellular homology-direct repair hdr result base edit also particularli well-
suit vivo applic improv safeti minim off-target paramount
activ non-divid cell target neuron hdr gener ineffici non-divid
cell achiev effici multiplex edit single-step
area hematolog sickl cell diseas beta-thalassemia oncolog ex vivo multiplex
edit creat next-gener car-t aml liver diseas antitrypsin
defici glycogen storag disord type ocular disord stargardt
diseas deliveri method includ electropor hematolog oncolog non-vir lnp
deliveri liver diseas viral aav deliveri ocular disord beam lead
hematolog oncolog program furthest along develop current lead-
optim stage expect show initi vivo data ind begin
sickl cell diseas beta-thalassemia
current develop two
complementari abe base edit approach sickl cell diseas scd transfusion-
depend -thalassemia tdbt use ex vivo electroporation-medi edit
patient hematopoiet stem cell hsc infus back patient
standard autolog stem cell transplant procedur see strong clinic
rational edit approach one applic inherit blood
disord fetal hemoglobin re-activ anoth uniqu scd direct correct
sickl cell mutat recent present encourag preclin data
program expect present addit preclin data
hemoglobinopathi program scientif medic meet ind file
anticip
allogen car-t therapi pediatr t-all aml optim allogen off-the-
shelf car-t therapi ideal incorpor multipl modif function modul
address gvhd graft reject also improv efficaci durabl
persist reduc neurotox light desir properti
believ beam base edit platform well-posit develop allogen
car-t therapi best-in-class potenti abil enact effici
predict multiplex done simultan edit edit would notabl
perform singl electropor step ex vivo set given lack
creat dsb would expect greater cell yield better character product
rel compet gene edit approach compar set shown
decreas viabil increas edit result format dsb
anti-trypsin defici aatd beam base edit approach uniqu
posit address aatd caus mutat abe precis
revert point mutat back correct base therebi allow product
normal wt importantli edit would simultan address lung
liver compon diseas restor secret remov
build-up toxic protein furthermor toxic mutant
correctli edit cell surviv benefit non-edit cell therefor
would expect compris greater proport total liver cell time
show strength discoveri effort develop novel
base editor six month capabl correct mutat human
cell effici vitro
glycogen-storag diseas type approach lnp-
deliv abe-correct two preval mutat caus diseas
point mutat compris patient
patient us respect identifi product candid
achiev edit effici allel harbor
mutat cell harbor mutat
stargardt diseas beam base edit platform well-suit address stargardt
diseas given preval mutat caus diseas point
mutat could correct adenin base editor preval also
common insofar ird concern pt us affect
mutat furthermor diseas model use tini spot stimuli suggest diseas
correct could achiev edit effici advantag
approach direct correct allow gene benefit normal
endogen regul ensur appropri protein level produc rather
risk product sub-optimal supranorm protein express aav
deliv exogen product identifi base editor capabl
edit approxim allel recombin cell carri human
valuat outlook
initi coverag outperform rate price target pt deriv
sum-of-part valuat compani seven preclin diseas program pediatr t-
aml scd tdbt aatd stargardt diseas program appli
multipl estim us/eu sale less high single-digit royalti per program valuat
year discount back risk-adjust discount rate
shown intellia neutral gene edit compani
posit preclin updat requir execut preclin
develop timelin ind submiss potenti licens deal signific
driver near-term share valu furthermor believ ind accept
deliveri modal result signific appreci
share posit read-through beam addit product candid
beam product candid may often differenti guid rna given
moreov platform compani believ number addit lever
upsid could continu drive compani long-term valu first
believ posit benefit licens collabor activ
industri partner would provid meaning sourc non-dilut revenu
potenti mileston payment royalti regard like retain
wholly-own econom mani program possibl prematur
sell right might evolv competit program seen
gene edit peer still see rational structur collabor
around non-cor therapeut area verv therapeut
maxim platform econom potenti see deal analog recent
collabor agreement sangamo neutral liana moussato
outperform laura chico wherebi sangamo receiv up-front
payment collabor certain neurolog disord achiev
demonstr proof-of-concept addit note
current pursu develop us eu see expans addit
territori japan china busi develop activ
meaning sourc non-dilut revenu potenti royalti final may
also gener addit valu intern advanc strateg partnership
addit edit technolog prime edit rna edit edit
applic plant gene edit also sourc potenti out-
gene edit tradit involv creation double-strand dna break dsb precis
target locat genom dna-sequ specif engin nucleas dsb
repair leverag natur dna repair mechan non-homolog end join
nhej homology-direct repair hdr directli address pathogen genet code
given diseas unlik tradit gene therapi approach viral machineri predominantli
adeno-associ viru aav lentiviru lv adapt deliv insert exogen genet
materi transgen patient cell function gene product express gene edit
allow greater specif genet modif instanc gain-of-funct mutat
address gene knockout delet dsb creat within mutat
sequenc result format insert delet indel frameshift prematur
stop codon follow nhej-medi repair disrupt target gene dsb gener
flank region target sequenc also result excis genet materi
subsequ non-express correspond pathogen protein result product
truncat non-funct protein furthermor gene edit also allow gene correct
dsb target genet sequenc interest follow dna natur repair
desir genet code exogen donor dna templat must also present
encourag repair hdr intend code gene addit may also incorpor
manner involv induct dsb safe harbor locu genom follow
incorpor novel gene cassett aid hdr templat overal specif
versatil gene edit notabl advantag gene therapi gener entail
rel non-sit specif transgen addit howev gene edit approach
promis limit therapeut modal result off-target toxic
insuffici on-target edit effici specif challeng deliveri gene
edit machineri desir cell especi vivo applic
four primari gene edit tool develop zinc finger nucleas zfn
transcript activator-lik effector nucleas talen variat mega-t
mani respect gene edit approach optim achiev
compar outcom mani context although widely-employ gene
edit tool also gener consid practic versatil
figur product site-specif nuclease-bas gene edit
figur non-homolog end join nhej homology-direct repair hdr follow
double-strand break dsb gene edit
follow format doubl strand break dsb endogen dna repair occur non-
homolog end join nhej result random indel homology-direct repair hdr
use templat dna strand precis repair
initi discoveri develop home endonucleas earli
allow dsb-trigger target dna repair non-homolog end-join nhej could
confer target recognit human cell zfn pioneer
neutral liana moussato becam first engin nucleas could recogn
target site endogen gene stimul genom edit zfn hybrid protein
fuse togeth dna-bind domain compris sever zinc finger protein array confer
target specif restrict endonucleas foki gener dsb target dna
zinc finger fusion site replac wt dna-bind domain endonucleas sinc
foki nucleas domain need dimer activ zfn must form dimer becom
activ gene editor effect doubl length recognit site
bp zinc finger per subunit zinc finger recogn dna sequenc
practic therapeut applic zfn hinder technolog complex
cost one sinc specif confer protein zinc finger domain easili
modul guid rna dna-specifi mechan base system zfn
also bia sequenc rich guanin zfn target must oppos
dna strand continu allow two monom close enough proxim
allow dimer format catalyt activ greatli limit amount avail
target amen effici edit addit zinc-finger-dna interact
shown modular natur zinc finger interact mostli independ dna
sequenc practic on-target effici off-target activ difficult predict
consider construct optim preclin test requir yield function
zfn often difficult reproduc nevertheless note zfn benefit
small size kb encod materi per dimer facilit deliveri
figur schemat zinc-fing nucleas
pioneer cellecti cll nc talen develop long zfn altern
endonuclease-bas genom edit tool fact two modal share mani similar
util foki dna-cleavag domain fuse protein-bas dna-recognit
domain form dimer engag effici edit activ talen howev incorpor
transcript activator-lik effector tale origin found pathogen bacteria infect
plant dna-bind domain tale made tandem array amino acid
repeat recogn singl base pair amino acid posit
repeat call repeat-vari di-residu rvd mani respect talen
limit mani way zfn requir engin novel talen protein
target dna site consider limit practic unlik zfn talen versatil
design target almost given dna sequenc howev talen also
largest major edit tool kb per dimer consequ stringent
packag constraint make least suit vivo deliveri surpris
cll focus talen develop exclus ex vivo car-t cell applic
figur schemat talen
note talen compos transcript activator-lik effector tale amino terminu
foki nucleas domain carboxyl terminu tale repeat compris amino acid
recogn singl base pair amino acid posit call repeat
variabl diresidu rvd shown red sequenc talen pair typic bp length
bluebird bio outperform advanc megat follow acquisit
privately-held pregenen megat modifi version talen edit fuse minim
tale domain dna recognit n-terminu meganucleas deriv
laglidadg home endonucleas lhe famili dna cleavag engin nucleas
primarili differ talen design use lhe rather foki catalyt
domain dna cleavag foki low intrins affin dna lack sequenc
specif dna cleavag target site affin specif entir depend tale
rvd array requir longer repeat avoid undu toxic nonspecif bind
contrast sinc meganucleas right show degre target specif shorter tale
array construct allow degre specif furthermor megat
engin singl chain design better facilit multiplex edit applic
avoid inappropri heterodimer well allow overal size edit
complex kb greatli decreas therebi provid greater deliveri flexibl limit
around adopt megat edit primarili practic engin process highli
challeng exampl given highli compact design difficult alter target specif
maintain appropri endonucleas activ activ highli depend
topolog whole target site bound nucleas thyme et al
current focus megtal technolog car-t hematolog applicationsmost recent
novo nordisk enter research collabor octob jointli develop next-
gener vivo genom edit treatment use megat edit hemophilia
figur schemat megat
pioneer precis bioscienc nc gene edit tool base engin
i-crei home endonucleas call arc nucleas arc nucleas uniqu gene edit
approach target specif dna-cleavag properti function
arc nucleas arc nucleas smallest genom edit tool kb therefor
easili packag aav vector focu preclin vivo pipelin
howev arc nucleas develop hamper similar constraint zfn talen
megat edit given all-protein structur protein-dna recognit furthermor
modular recognit domain zinc finger tale associ
arc edit optim arc nucleas engin even difficult achiev also like
edit tool immunogen respons also found nhp studi nucleas i-
crei home endonucleas deriv chlamydomona reinhardtii
cluster regularli interspac short palindrom repeat crispr -associ
sinc initi demonstr util system mammalian cell
techniqu revolution genom edit research therapeut applic due
simplic design consider versatil spawn launch first biotechnolog
compani focu modalitynam crispr therapeut crsp nc edita medicin
nc intellia neutral
two-compon gene edit system compris protein natur
occur nucleas origin discov part bacteri adapt immun system
commonli streptococcu pyogen singl guid rna sgrna system
protein direct effici double-strand cleavag sgrna use direct
genom sequenc interest short motif call protospac adjac motif
pam must also adjac recognit site act switch nucleas
trigger double-strand dna break within target sequenc target specif
domain nucleic acid base protein-bas like zfn talen megtal edit
complex direct genom sequenc interest significantli easier
optim howev make dsb target sequenc therapeut applic
remain hamper mani properti genom edit
tool one two simultan dsb creat resid close proxim
chromosom defin delet result high frequenc cleavag event occur
differ chromosom transloc may occur result proto-oncogen
activ furthermor although shown high edit effici effect
nhej-medi repair indel gene disrupt abil effect hdr-mediat gene
correct insert greatli limit due deliveri constraint enhanc
packag requir ad donor dna templat hdr competit nhej
cell prefer condit import limit hdr also gener
activ within divid cell
figur schemat
mean deliveri genom edit construct crucial sometim limit
consider therapeut applic depend factor size packag
cargo target cell interest
ex vivo gene edit ideal suit edit cell hematopoiet origin target cell
remov patient bodi effici edit expand transplant back
patient leverag standard hematopoiet stem-cel transplant hsct protocol
way genet hematolog disord sickl cell diseas scd address cancer
cellular immunotherapi applic similarli well suit ex vivo gene edit patient
donor immun cell edit ex vivo enhanc anti-tumor function
electropor microinject edit commonly-util
approach use electropor introduc nucleic acid protein cell
discharg electr puls across cell membran deliv edit complex
preform ribonucleoprotein rnp complex rnp particularli attract form
cargo deliveri ex vivo applic sinc feasibl deliv via
electropor ensur genom integr long-term express
fewer off-target effect addit electropor microinject direct physic
deliveri edit complex directli target cell also success use
ex vivo ensur specif howev process labori impract
achiev edit larg number cell final mrna also success deliv
altern cargo rnp subsequ translat correspond
gene edit machineri deliveri primari advantag mrna smaller
size rel rnp facilit deliveri offer degre signal
amplif mrna stabli resid within cell sever day although
alway desir
vivo gene edit direct deliveri gene edit machineri patient best suit
edit cell remov easili transplant back patient compar
ex vivo deliveri howev vivo deliveri much challeng greater effort need
made ensur suffici deliveri proper tissu without gener undu off-target
toxic commonli vivo deliveri util either viral machineri predominantli aav
lipid nanoparticl lnp deliv either mrna dna rnp payload
lipid nano-particl lnp deliveri lnp deliveri simpler inexpens
two anionic-charg mrna sgrna anion rnp stabli
encapsul cation lipid polym polym includ helper lipid cholesterol
polyethylen glycol aid extend blood circul time prevent
aggreg control particl pharmacokinet facilit payload
endosom escap cellular uptak technolog non-vir also benefit
genom integr low immunogen could allow repeat dose
fact lnp deliveri increasingli clinic valid recent approv
rnai therapeut onpattro nc howev lnp deliveri greatli
limit scope potenti tissu target vesicl tremend
tissu tropism liver properti cours ideal target liver
goal limit use tissu
adeno-associ viru aav deliveri order effici address cell target outsid
liver vivo edit aav advanc attract modal like
lnp aav demonstr inher tissu tropism leverag select
target tissu interest includ liver eye brain muscl lung furthermor
demonstr clinic trial aav-medi gene therapi aav
exhibit clinic manag low immunogen howev use aav
gene edit limit packag constraint vector normal
encod kb genet cargo constraint mostli inconsequenti
smaller edit construct megat zfn meaning impact util
larger edit construct talen base edit especi
addit correct dna templat must also packag vector
circumv problem case edit possibl use two
separ aav vector one nucleas one sgrna donor
templat although effect reduc edit effici final addit
drawback use aav includ signific cost associ manufactur
vector clinic scale potenti enhanc off-target toxic
immunogen sustain express
figur method deliv genome-edit tool
adapt doudna wedbush secur
figur mode nucleas deliveri
adapt zhang et al wedbush secur
propertynanoparticlesvirusesribonucleoprotein rnp featur applic cation lipid polym lipid nanoparticl lnp use encapsul molecular cargo facilit cellular entri adeno-associ virus aav commonli use clinic deliveri vehicl gene therapi purifi protein guid rna deliv via electropor stem cell extract patient treat blood disord sickl cell diseas microinject directli target cell interest also possibl nmpayloadmrna dna rnp least commonli use dnapreform enzym complex advantages-inexpens rel easi produce-no genom integration-low immunogenicity-broad tissu target possibilities-clinically-establish method-efficient-no genom integration-no long-term express fewer off-target effectsdisadvantages-limit capac tissu targeting-limit cargo size-undesir integr risk-sustain express lead off-target effects-immunogenicity-high cost manufactur challenges-wil enter cell without engin addit reagents-potenti immunogen vivo-unprotect rnp risk degradationprimari target liverliv eye brain lung muscleoocyt stem cell t-cell propertydnamrnaprotein transcript nucleusyesnonotransl cytoplasmyesyesnoend product function nucleusyesyesyesstart time hrsstabilitygreatgood modifi weeksever day hrsintegr riskyesnonooff-target activityhighlowlow
origin david liu colleagu harvard univers broad institut
among scientist pioneer initi develop mammalian
cell base edit genome-edit method directli gener precis point mutat
genom dna cellular rna without directli gener dsb requir dna donor templat
reli cellular hdr process conceptu similar gene edit
entail use guid rna sequenc provid specif target genom sequenc
well modifi ca machineri enabl nucleic acid cleavag base edit howev
edit machineri also incorpor deaminas protein catalyz remov amino
group target nucleic acid base facilit convers correct desir
base base edit higher level precis singl base level tool
describ pencil contrast scissors-lik function compet genom edit
figur base edit offer pencil-lik precis rel genom edit tool
mechan base edit
current two class dna base editor describ cytosin base
editor cbe convert c-g base pair t-a base pair adenin base editor abe
convert a-t base pair g-c togeth editor encompass four possibl
transit point mutat roughli known pathogen point mutat although
current address eight possibl transvers point mutat
cytosin base editor cbe cbe edit first base editor-grna complex bind
target locu dna base pair occur grna target dna
strand catalyt impair protein denatur displac small
segment single-strand dna ssdna form expos loop target
locat versu crispr edit protein act dsdna induc
dsb point deaminas enzym fuse modifi
accept ssdna substrat convert target base respect deamin
deriv cytosin uracil uracil normal found rna
resembl base pair thymin natur correct detect
dna sequenc process allow convers desir
base edit intermediari howev natur convers also compet
natur cellular repair process base excis repair ber wherebi enzym
uracil n-glycosylas ung recogn u-g mismatch cleav bond
uracil dna backbon usual result revers back c-g overcom
uracil glycosylas inhibitor fuse edit complex inhibit
ber facilit t-g convers still natur pair
guanin still locat non-edit strand origin form c-
 base pair need replac adenin complet base pair edit
modifi enzym afford nickas function therefor
abl induc single-strand dna break nick non-edit strand enabl
natur dna repair mechan repair non-edit strand read
edit strand templat result form complet desir base pair edit
c-g t-a see figur cbe therefor abl address pathogen
adenin base editor abe also develop abe addit cytosin base
editor cbe perform a-t g-c convers abe edit first deamin
inosin intermediari correct develop adenin
deaminas first difficult cbe sinc known
adenosin deaminas enzym capabl act ssdna overcom
evolv escherichia coli trna adenosin deaminas enzym tada found
activ mammalian cell engin heterodimer protein incorpor
evolv tada monom wt non-catalyt tada monom nickas
singl chain differ cbe abe requir function inhibit ber
inosin intermediari abe perform a-t g-c convers abl
address pathogen point mutat despit correct one six possibl
base pair convers consequ natur common process
spontan cytosin deamin occur cell alway correct
figur cytosin adenin base editor
figur technic detail cbe base edit
figur technic detail abe base edit
note schemat adenin base editor abe -mediat dna base edit convert base pair
gc base pair shown current abe contain one wild- type tada structur monom one evolv tada
catalyt monom loop format expos small region single- strand dna ssdna within
deamin heterodimer wild-typ tadaevolv tada heterodim
liu et al adapt liu et al
advantag base edit
highli precis predict
base editor highli narrow activ window nucleotid wide furthermor
one type base edit possibl within window ultim enhanc precis
predict edit reaction
avoid double-strand break insertion-delet indel
one biggest drawback gene edit potenti unintend
consequ follow creation dsb dsb normal caus level indel format
possibl result genet alter chromosom rearrang
transloc theoret pathogen potenti proto-oncogen activ
dsb also occur off-target involv cleavag undesir dna site highli
homolog target site recent potenti on-target effect also
elucid dsb repair may possibl involv larg delet extend sever kilobas
pair length addit complex genom rearrang rather
previous expect bp length indel follow dsb creation kosicki et al
potenti signific collater damag off-target and/or on-target effect greatli
rais safeti hurdl gene edit especi vivo applic
like significantli extend preclin lead time regulatori scrutini result product
candid case base edit howev dsb creat therefor indel
format expect occur consider lower frequenc shown
perform edit indel format rel greater indel format
correspond edit figur therefor base edit theoret safeti
figur high precis effici correct base edit vs tradit gene
effici base edit aid fact activ divid non-
divid cell need donor hdr dna templat one main drawback
hdr normal restrict phase cell cycl therefor
effici activ divid cell ultim diminish overal effici
limit vivo applic particularli slowly-replicating/non-repl cell type
neuron muscl base edit convers benefit requir hdr repair mechan
therefor edit cell point cell cycl furthermor unlik edit
base edit requir exogen dna templat given edit mechan
specif design make singl base edit simplif process enhanc
ration applic base edit
precis correct pathogen point mutat
point mutat genet mutat singl nucleotid base substitut anoth
within sequenc dna alway pathogen diseas mutat associ
sever alter defunct express function respect encod protein
estim roughli total genet variant current associ diseas
half result point mutat figur given base edit specif
enabl single-nucleotid base substitut beam technolog best suit effici
address pathogen point mutat current abe cbe base editor could
potenti address known point mutat associ diseas total genet
mutat a-t g-c c-g t-a respect
figur distribut human pathogen variant includ point mutat
 represent classif human pathogen genet variant clinvar databas
access may shown note text sampl bia owe extens use short-
read sequenc analyz genom divers possibl represent distribut base pair
chang need revers pathogen point mutat repres red wedg part shown
percentag repres base pair chang note pie chart transit mutat
shown white text transvers mutat shown black text indel small insert delet
given potenti off-target on-target activ genome-edit tool abil
administ multipl sequenti concomit edit cell becom less viabl
probabl result deleteri event would significantli elev case base
edit howev techniqu show greater effici less indel format
abil administ multipl edit cell becom feasibl especi
import potenti vivo applic qualiti control measur cant conduct
edit perform although also signific ex vivo applic achiev
suffici cell yield crucial
vivo deliveri non-divid cell target
gener vivo deliveri necessit higher degre specif edit effici
ex vivo applic cell vivo assess select viabil
manner achiev ex vivo regard requir similar
multipl gene edit see beam base edit platform potenti
advantag specif edit effici better allow vivo deliveri furthermor
given base edit effici perform non-divid cell allow better
applic wider varieti diseas target particularli liver diseas ocular
disord cell target mostli termin differenti
specif consider base edit
although see advantag beam base edit platform term specif edit
effici rel genom edit platform still number potenti advers
consequ consider mind
mention possibl one target base could resid within given
activ window result undesir bystand edit event presenc addit
edit neg consequ extra edit produc undesir amino acid
disabl code protein howev expect occur scenario
exampl addit edit may chang codon redund altern chang
result amino acid therefor express protein anoth case code amino acid may
chang bystand edit meaning effect code protein function
accept bystand desir genet effect gene silenc one base edit
suffici disabl pathogen protein silenc would maintain final problemat
bystand edit avoid ration engin base editor direct
altern activ window bystand edit expect fact one paper cbe
engin harbor truncat exhibit much narrow activ window
within protospac high accuraci variant develop predominantli edit
posit select edit tan et al
guide-driven off-target edit result grna bind wrong target genom
sequenc occur two sequenc high degre homolog event
edit base within wrong activ window unintend base edit akin
bystand edit describ could occur gener potenti guide-driven off-target
effect major hurdl gene edit approach specif confer guid
ca enzym machineri complic manag ration grna
select editor engin
type off-target effect characterist base edit alon crispr involv
potenti unintend deaminas activ non-guid target dna sequenc
potenti larg minim given deaminas unabl act dsdna theoret
could act region dna replic fork ssdna substrat form cours
likelihood occur also depend grna target homolog inde
conduct preclin analys show differ abe deamin
background deamin non-guid driven set case cbe deamin
shown base-deamin rate base believ within clinic
accept risk-benefit profil given rate lower spontan deamin rate
typic observ somat cell expect nonetheless continu work minim
effect
sum current limit scope address mutat base edit
address view rang edit beam base edit system make
competit profil compar current gene edit strategi
deliveri base editor
pursu three separ deliveri strategi base edit platform in-lin
aforement strength modal ex vivo electropor hematolog
diseas cancer vivo lnp-mediat deliveri liver diseas vivo aav deliveri
ocular disord
ex vivo electropor use electropor deliv base editor
either mrna rnp directli target hematopoiet cell hematolog
oncolog indic process valid deliveri modal
particular electropor theyr use use dozen clinic
trial referenc fda drug master file healthi donor hematopoiet
stem cell shown abe edit effici greater figur
beam lead base edit program sickl cell diseas scd beta-thalassemia
well lead car-t program pediatr t-cell acut lymphoblast leukemia t-
acut myeloid leukemia aml implement ex vivo electropor
look forward vivo proof-of-concept includ engraft data ex
vivo edit cell valid
vivo lipid nanoparticl lnp deliveri mention lnp deliveri increasingli
valid deliveri modal nucleic-acid base treatment intend liver
shown rnai therapeut alnylam mrna therapeut
deliveri intellia albeit nhp among other develop
sever proprietari lnp formul shown effect abe edit
mice low dose figur plan identifi lead lnp formul
optim biodistribut hepatocyt nhp carri forward use
clinic trial beam lead liver diseas program includ antitrypsin
defici aatd glycogen storag disord type implement
figur preclin valid ex electropor lnp deliveri
vivo aav deliveri develop aav vector deliv base editor vivo
correct ocular disord howev larg size encod
base editor kb base editor includ sgrna unabl
packag within kb constraint aav vector overcom
advanc novel split base-editor dual-aav strategi abe cbe split
amino-termin carboxy-termin half fuse half fast-
splice split intein design intein half packag separ aav
vector ultim reconstitut full-length base editor complex follow two
vector co-infect target cell note reconstitut process
two base editor halv leverag natur post-transl process mechan
intein protein splice element facilit excis intein
sequenc precursor protein two extein end ligat form
final protein product case unmodifi base editor complex importantli
preclin data demonstr split-intein reconstitut base editor exhibit
compar edit effici rel full-length base editor addit
also made signific inroad aav optim split intein base editor
construct develop dual vector total vector dose in-lin current gene
therapi applic yield therapeut relev edit effici
mous brain liver retina heart skelet muscl
without edit tissu tropism levi et al figur
split base-editor dual aav system also abl correct mutat
mous model niemann-pick diseas anoth paper system vivo
deliveri
mous model
phenylketonuria pku result mrna correct rate restor
phenylalanin hydroxylas pah enzym activ revers light fur
phenotyp villig et al sum encourag current progress
develop split base-editor dual-aav show highli effici edit yield
compar full-length base editor go forward anticip addit
improv edit effici near clinic emphas
current experi consid tissue-specif optim measur use
figur schemat split-intein base editor
intein reconstitut strategi separ encod protein fragment fuse split-intein halv splice
reconstitut full-length protein follow co-express
figur system inject editor result cytosin adenin base edit
heart muscl liver
schemat retroorbti inject experi six-week-old mice treat retro-
orbit inject vg total week organ harvest genom dna
unsort cell sequenc cytosin left adenin right base edit target aav
aav-abemax respect indic organ comparison adenin base edit
aav-medi split-intein abemax grey bar trans-mrna splice white bar trans-
splice construct modifi enabl direct comparison replac muscle-specif
promot cbh promot ubiquit express replac dmd-target sgrna
sgrna bar repres mean mice
figur aav-medi cytosin adenin base edit
schemat retro-orbit inject brain mice harvest week
inject vg total php eb abemax aav target vg
php eb gfpkash aav process analys describ cytosin base edit unsort
grey gfp green cortic cerebellar cell follow procedur describ
futur develop base editor
dna base edit alreadi shown abil gener singl point mutat
potenti correct pathogen transit point mutat futur expect addit base
editor engin allow expans scope address mutat
address addit highlight develop novel ca nucleas may abl
incorpor base editor even versatil
improv breadth action base edit target pam expans
edit breadth amen dna target base edit inher
limit pam restrict nucleas activ conting first recognit
appropri pam motif flank target dna sequenc case ngg pam
compat larg limit recognit g-rich sequenc genom addit base
edit activ base editor optim pam motif locat
nucleotid away target base may action given target point
mutat moreov much effort underway expand action target
discov novel protein deriv bacteri speci streptococcu pyogen
distinct pam motif may better suit given target sequenc exist
variant also optim continu evolut expand pam
compat liu co-work recent demonstr phase-assist evolut could
use develop novel variant display bind toward non-g pam sequenc miller
et al three novel variant collect recogn nrnh pam
 togeth previous report variant nishimasu
et al hu et al allow base editor target address
point mutat one exampl involv success a-t g-c edit scd mutat use
previous inaccess pam motif importantli paper also show evolv
variant similar higher overal dna specif on-target activ tradit
activ ngg pam site improv prior studi show broaden
pam target capabl increas proport off-target edit
improv base editor specif minim off-target activ
addit potenti off-target activ base editor base editor
also exhibit background deaminas activ independ recognit like aris
deaminas domain intrins affin dna recent liu cowork develop
method effici screen select cbe variant substanti decreas
off-target edit magnitud lower averag retain
appreci on-target activ figur importantli also show optim cbe
variant minim off-target edit also demonstr higher level
form unwant edit includ fewer indel less dna off-target
edit less rna off-target edit doman et al
figur balanc on-target edit greatli decreas edit
on-target edit versu averag off-target edit cbe studi axi reflect mean
on-target control edit on-target locu use orthogon r-loop assay axi
reflect mean off-target edit six orthogon r-loop green box indic cbe variant
substanti decreas off-target edit retain appreci on-target activ
supplementari fig fig mean valu individu site averag maximum on-
target averag off-target edit construct decreas edit event
axi reflect averag edit across six on-target protospac highli edit cytosin within
protospac axi reflect averag off-target edit orthogon r-loop assay
develop rna base edit
addit dna base editor describ also develop rna base editor
add addit versatil genom edit toolbox obviou potenti
advantag rna edit safeti deleteri off-target activ unintend genet
manipul would transient perman natur rna base edit could also tune
protein express diseas without genet origin edit mrna encod
sodium channel modul pain signal transmit brain therebi
potenti treat chronic pain without opioid without risk perman alter
gene dna edit particular applic pursu altern approach
rna edit antisens oligonucleotide-adar complex rna edit also expand
set address target clearli action dna edit includ
abl target mrna encod protein involv regul activ function
protein post-transl modif phosphoryl glycosyl
licens exclus right broad institut two rna base editor a-to-i
editor call repair c-to-u editor call rescu current
incorpor disclos develop program offer compani addit
versatil base edit capabl
rna edit programm a-to-i replac repair rna edit build upon
initi insight function famili enzym call adenosin deaminas
act rna adar catalyz hydrolyt deamin adenosin
inosin repair catalyt dead rna-guid enzym provid target
specif fuse deamin adenin a-c mismatch
inosin known exampl natur a-to-i edit code region mrna suggest
inosin context read guanin translat
rna edit specif c-to-u exchang rescu rescu adenin deaminas
domain synthet evolv cytidin deaminas effect
catalyz c-to-u convers dsrna like repair deaminas fuse
catalyt inact provid specif one studi research
demonstr potenti rna edit rescu drive -catenin activ
consequ cellular growth abudayyeh et al perman
upregul cellular growth dna edit would undesir could lead
develop cancer could prove efficaci transient express
acceler wound heal respons acut injuri exampl demonstr
potenti therapeut role rna base edit
figur rna edit repair
matsouka adapt cox et al
develop nucleas base edit
modif evolut known enzym greatli expand versatil
genom edit develop altern ca enzym significantli less
character offer potenti even greater option genom base edit
applic licens exclus right broad institut use
nucleas gene base edit hold option exclus licens certain patent
patent applic direct nucleas formerli edita
nucleas base edit previous develop type-v crispr
effector challeng part due high temperatur requir
character famili member preclud therapeut applic recent
direct evolut enzym includ introduct gain-of-funct
mutat facilit develop feasibl gene edit platform point
differenti platform includ target site ideal pam
found t-rich posit bp upstream protospac particularli
attn limit off-target activ found significantli less
test site smaller compact amino acid size rel
system would facilit effici packag aav
vector vivo applic strecker et al
nucleas base edit nucleas formerli type crispr-
ca nucleas explor altern genom edit system
unlik requir short nt crispr rna crrna trans-
activ crrna tracrrna direct target specif recogn target site
t-rich pam previous requir extend tttv pam motif
 greatli restrict action target rel
recent howev engin exhibit superior on-target activ
substanti expand target rang reduc off-target effect rel prior
gener nucleas kleinstiv et al furthermor shown
potenti applic base edit well li et al
figur protein domain structur nucleas
figur comp tabl lead gene edit platform
base edit fusion guid rna fusion cbe snp revers gene knockoutprotein-rna bp bp pam pam sequenc bystand edit kb w/o grna difficultlow nucleas sgrnagen insert delet replac protein-rna bp bp pam pam kb w/o grna moderatelow highzinc finger nucleas nucleas zinc-fing array gene insert delet replac bp dimer non-g-rich sequenc kb dimer easyhighlowtalencl foki endonucleas tale array gene insert delet replac target base must kb dimer difficultmoderatelowmega-talbluelh meganucleas tale array gene insert delet replac bp topolog due compact kbseasyhighmoderatearcu dtilengin i-crei-deriv meganucleas gene insert delet replac bp topolog due compact kb easyhighmoderatecost engineeringspecificitymultiplex compatabilitycompani platformin vivo deliveri easerecognitionsit edit dsb target constraint edit construct constructs
sickl cell diseas -thalassemia
current develop two complementari abe base edit approach sickl cell
diseas scd transfusion-depend -thalassemia tdbt use ex vivo
electroporation-medi edit patient hematopoiet stem cell hsc
infus back patient standard autolog stem cell transplant procedur
see strong clinic rational edit approach one applic
inherit blood disord fetal hemoglobin re-activ anoth uniqu scd direct
correct sickl cell mutat recent present encourag preclin data
program expect present addit preclin data
hemoglobinopathi program scientif medic meet ind file
anticip
scd sever inherit blood diseas caus singl point mutat beta globin
gene result product pathogen sickl hemoglobin hemoglobin
hb specif pathogen hb stem missens mutat gag gtg
caus substitut valin glutam acid sixth posit beta globin chain
 amino acid substitut caus conform chang beta globin
protein manifest red blood cell rbc hold rigid sickl shape low oxygen
condit furthermor sickl rbc gain capac polymer encourag
obstruct blood vessel cell prematur death ultim lead anemia
sever pain vaso-occlus crise voc increas infect risk stroke earli death scd
affect estim person us
figur etiolog sickl cell diseas
limit current therapeut approach despit clear well-known
genet natur scd remain underserv exist treatment strategi mostli
support natur allogen hematopoiet stem cell transplant hsct
current potenti cur therapi avail demonstr five-
year event-fre surviv overal surviv rate respect
per intern survey hla-ident sibl transplant gluckman et al
howev hsct limit donor elig ww
correspond risk graft-versus-host diseas gvhd gr incid even
matched-s donor hsct co-morbid otherwis treatment
option larg manag diseas symptom includ analgesia vaso-occlus
crise voc hydroxyurea anti-infect recent two disease-modifi
treatment approv fda adakveo novarti nc oxbryta
outperform liana moussato agent repres meaning
advanc treatment scd fda-approv medic sinc
hydroxyurea l-glutamin endari emmau life scienc also hemodynam
modifi agent leav much room improv
adakveo crizanlizumab adakvea iv-administ mab anti-
p-selectin receiv approv treatment voc
scd pt unrespons either hydroxyurea l-glutamin base
result registr sustain trial approv
dose level adakveo demonstr improv annual incid
voc event vs placebo amount annual
hospit also meaning reduc patient receiv
adakveo rel placebo vs day respect safeti
profil mostli toler
oxbryta voxelotor oxbryta oral small molecul inhibitor hb
polymer receiv acceler approv
treatment scd base result registr trial
compar placebo oxbryta associ reduct
acut voc increas higher dose annual incid
vs placebo dose-depend increas hemoglobin also
observ patient achiev increas
g/dl high dose low dose placebo group respect oxbryta
also gener well toler somewhat greater rate headach
gastrointestin symptom diarrhea abdomin pain compar
beta-th inherit blood disord caus one least mutat
hemoglobin beta gene result reduc product function hemoglobin
sever form diseas transfusion-depend beta-thalassemia tdbt patient often
requir eight blood transfus per year avoid clinic manifest reduc
function hemoglobin includ failur thrive persist infect life-threaten
anemia global preval tdbt roughli patient vari tremend
region patient concentr mediterranean middl east south asia
limit current therapeut approach scd limit
treatment option avail tdbt support natur allogen hsct
similarli potenti cur also limit donor elig risk
gvhd comorbid recur transfus patient
requir on-going chelat therapi avoid iron load associ organ
damag howev treatment burdensom associ signific
toxic consequ low adher current one fda-
approv therapi beta-thalassemia reblozyl luspatercept bristol-my
approv treatment anemia adult patient
requir regular red blood cell transfus registr believ trial
patient receiv subcutan reblozyl experienc signific reduct
transfus need treat patient achiev reduct
number transfus one third versu placebo-tr patient
moreov efficaci encourag remain signific room
improv novel therapi addit remain safeti concern
reblozyl possibl increas risk hypertens thromboembol
appendix summari tabl fda-approv therapi scd beta-
beam solut edit approach hemoglobinopathi
current develop two complementari abe base edit approach scd tdt
one applic inherit blood disord fetal hemoglobin re-activ
anoth uniqu scd direct correct sickl cell mutat
benefit hbf first identifi individu possess benign condit
hereditari persist fetal hemoglobin hpfh signific hbf product continu
well adulthood past normal shutoff point develop usual three month post-
birth adult-typ hemoglobin produc peopl hpfh also
harbor scd tdt-caus mutat gener asymptomat exhibit milder form
blood disord increas benefit shown patient higher express hbf howev
scd/tdt patient without hpfh diseas onset normal occur normal shutoff point
hbf product therebi provid support protect role hbf
moreov hpfh caus either larg delet -globin gene singl base
chang regulatori region hbf -globin gene
increas express hbf prevent bind one repressor protein
given pathogenesi aim recreat hpfh phenotyp base
edit effect abe-medi ag base chang promot region
would prevent bind repressor protein therefor lead re-activ
hbf express notabl approach also allow candid evalu
scd tdt patient
figur fetal-to-adult hemoglobin switch normal develop sickl cell diseas
figur base edit re-creat hereditari persist fetal hemoglobin hpfh
note -thalassemia scd patient natur hpfh mutat asymptomat experi
much milder form diseas hpfh result natur occur singl point mutat
regulatori region hbf gene mutat lead increas express
fetal hemoglobin prevent bind one g-globin repressor protein
preclin data demonstr high edit effici healthi donor cell
precursor rbc would edit ex vivo demonstr greater edit
abe post-electropor maintain week post-transpl
immunocompromis mice figur also separ experi edit cell
underw differenti erythroid cell exhibit significantli upregul -globin
express proport total globin vs unedit cell therebi
function re-creat natur occur hpfh mutat figur
overal believ earli demonstr effici edit vivo mous studi
encourag express hbf level believ suffici clinic benefit
ratio hb hbf like correct given function mimic
asymptomat sickl cell trait moreov note data larg in-lin edit
effici achiev compet gene edit strategi compar preclin model
believ beam base edit candid could still prove best-in-class given technolog
demonstr lower rate off-target activ could support better safeti long term
express addit continu process develop effort abe
candid remain addit upsid potenti candid optim
figur retent edit hematopoiet stem cell
note cell healthi donor edit inject nbsgw mice day recoveri
high chimer achiev similar level unedit sampl measur
edit achiev retain engraft nbsgw mice week
note edit scd trait cell differenti erythroid cell shown edit rate
promot detect post electropor continu rise erythroid
differenti gener natur occur hpfh mutat significantli upregul g-globin
erythroid differenti measur uplc similar result observ non-scd trait donor
approach direct correct sickl cell mutat
scd result singl point mutat gag gtg strong rational
use beam base edit platform directli correct caus point mutat
result restor normal hemoglobin product correct diseas specif beam abe
make singl a-to-g edit would convert pathogen amino acid valin alanin instead
notabl substitut repres wt beta-globin would glutam
posit nevertheless repres non-pathogen naturally-occur variant refer
makassar variant function like wt beta-globin
preclin data identifi base editor demonstr correct
sickl cell point mutat function makassar variant primari fibroblast isol
patient scd well greater correct cell scd trait figur
note although expect continu abe optim improv edit effici
correct level remain correct hb studi suggest may suffici
figur singl base chang abe convert makassar variant primari
fibroblast deriv scd patient
note abe screen scd patient deriv fibroblast identifi base editor demonstr high
level edit sickl cell point mutat makassar variant addit abe variant base
variant screen edit effici sickl trait cell variant achiev retain
high edit rate hour post-electropor erythroid differenti
sickl cell diseas section competit landscap better contextu
beam preclin data rel compet approach crsp other
base edit compon expect deliv ex vivo set
electropor well-valid non-vir physic deliveri method temporarili increas
permeabl cell therebi allow entri base edit machineri remov
theoret concern associ viral integr seen gene therapi approach
neg impact sentiment around blue lentiglobin exampl see note
furthermor viral manufactur also expens also gener neg
sentiment like abl produc edit cell lower cost
good
beam hpfh program near ind-en studi mostli involv effort
fulli character edit cell evalu long-term persist edit
intend schedul pre-ind meet fda confirm path ind file
appropri ind file current plan direct beta-globin correct
approach plan conduct addit edit optim effort mous engraft
studi move ind-en studi addit preclin updat scd/tdt
program includ long-term vivo data expect
ex vivo car-t candid pediatr t-all aml
car-t therapi involv ex vivo engin patient autolog donor allogen
cell express chimeric-antigen receptor enabl high-affin recognit
correspond tumor-associ antigen taa engin cell transplant
back patient follow standard condit regimen usual cyclophosphamid
fludarabin car-t cell abl specif recogn elimin target
cancer cell immune-medi cytotox mechan moreov fda
approv two car-t therapi sinc autolog car-t kymriah
yescarta pediatr dlbcl continu commerci limit manufactur
process constraint high cost potenti fatal car-t-associ toxic name
cytokin releas syndrom neurotox note expect cost
associ autolog cell therapi go time improv
manufactur process optim approach like remain limit de-
central manufactur longer vein-to-vein wait time mostli driven requir
bridg therapi refractori patient apheresi cell expans lower number
good qualiti cell patient-deriv cell show diminish chemotherapy-rel fit
given limit research increasingli focus develop allogen
off-the-shelf cell therapi promis signific advantag autolog
counterpart one use healthi donor cell usual peripher blood
mononuclear cell pbmc allogen candid produc scaled-up industri
process wherebi high number cell dose produc cryopreserv singl
donor dramat reduc cost good therapi administ
patient significantli faster even demand improv outcom
requir patient wait treatment undergo bridg therapi particularli relev
refractori patient rapidli progress cancer furthermor shown healthi
donor cell suffer chemo-rel reduc fit constitut greater
number earli memori phenotyp cell
associ improv outcom
howev despit promis allogen cell therapi develop also
hinder set limit promin donor-deriv cell
foreign patient high risk patient develop graft-versus-host diseas
gvhd primari caus morbid death patient receiv allogen stem-
cell transplant across indic especi pertin given gvhd primarili
mediat cell furthermor allo-immun wherebi patient develop
format donor-specific-hla antibodi graft reject occur greatli limit
car-t cell long-term persist weeks-to-month vs months-to-year autolog car-t
cell consequ efficaci allo-immun also sever restrict abil re-dos
allogen therapi final potenti patient-donor hla mismatch
stringent condit regimen may need associ increas toxic
right
moreov although complic could potenti mitig creat distinct cell
product bath hla subtyp patient-donor compat approach also impract
current approach optim allogen cell therapi center either
elimin function t-cell receptor tcr express car-t cell gene edit
use non- cell nk cell cell inher non-
alloreact contrast tcr determin alloreact figur
figur comparison autolog allogen car-t cell
good calcul drawn harrison et al compar current approv car-t
autolog hypothet allogen car-t product deriv healthi donor cell use
central manufactur facil across sever distinct geographi on-shor near-shor off-shor
regard cost assum higher scenario us central manufactur also
assum scalabl cost save base market penetr address us hematolog
malign market patient treat per year lever cost save model larg
consequ central manufactur drive cost relat ancillari materi
transport logist skill labor consum materi note signific
proport cost autolog allogen approach vs respect cost
licens royalti sale cost captur calcul final note assumpt
applic allogen cell therapi compani exampl report use ipsc-
deriv nk-cell platform produc engin nk-cell product cost assum scale
product lot product
adapt depil et al fraietta et al harrison et al wedbush secur
characteristicautolog -t cellsallogen -t cell origin donorpatienthealthi donorproduct manufactur process complex logist delay leukapheresi -t cell administr variat t-cell characterist accord patient immun characterist influenc previou treatmentsscaled-up industri process high number cell produc cryopreserv singl donor batch immedi avail patient treatment possibl standard cell characteristicsclin indic hematolog malign demonstr activ approv product solid tumorshematolog malign on-going trial solid tumor main issues/risk cytokin releas syndrom neurotox -relat gene modif potenti long-term side effect b-cell aplasia -t cell cytokine-releas syndrom neurotox and/or gene editing-rel gene modif gvhd allogen cell reject toxic case intens lymphodepletioncel qualitypoor chemo-rel reduc fit greater patient-to-pati variabilitygood greater number earli memori phenotyp cell associ improv outcom vein-to-vein process time week driven mostli need bridg therapi weekspersist intermediate-to-long month year short-to-intermedi week month re-dos limit number cellsnot limit number cell risk allo-immun format donor-specif anti-hla antibodi current high despit improv effici cogs/dos moder cog/dos
figur manufactur allogen car-t cell
note allogen chimer antigen receptor cell singl manufactur batch potenti benefit
multipl patient manufactur process allogen car-t cell product start sourc third- parti healthi
lymphocyt collect leukapheresi technolog viral vector- mediat transgenesi gene knock-
mediat gene edit enabl perman insert recombin dna code possibl addit
gene suicid gene co-stimul receptor said lymphocyt technolog also elimin express
cell receptor tcr said cell exampl gene editing- mediat tcr knockdown cell
expand use anti- bead cytokin remain tcr- posit cell magnet remov
use anti- tcr antibodi vial fill allogen cell product store frozen
ship hospit need
beam solut multiplex base edit allogen cell therapi
optim allogen car-t therapi ideal incorpor multipl modif function
modul address gvhd graft reject tcr knockout also
improv efficaci multi-antigen target durabl persist immuno-
suppress blockade/knockout fratricid resist reduc neurotox
modifi co-stimulatori domain light desir properti believ beam
base edit platform well-posit develop allogen car-t therapi best-in-class
potenti abil enact effici predict multiplex done simultan
edit edit would notabl perform singl electropor step ex vivo
set given lack creat dsb would expect greater cell yield better
character product rel compet gene edit approach compar set
shown decreas viabil increas edit result format dsb
unintent disrupt non-target gene function
valid base edit platform preclin studi show abil make
simultan multiplex edit high effici without gener
chromosom rearrang specif highlight simultan cbe-direct knockout
trac base edit effici shown donor cell would
correspond minim graft reject gvhd enhanc efficaci persist
respect importantli experi show differ edit effici
edit target alon simultan edit target furthermor edit
correspond cell achiev complet loss encod trac gene
protein well loss express figur
figur simultan base edit donor cell car-t
addit preclin studi show superior base edit
edit includ show genom rearrang form trac
target versu detect rearrang figur
figur detect transloc triple-edit cell cbe compar
crispr-edit cell also show decreas viabil greater number simultan edit
perform viabil consist base edit cell figur final
show triple-edit highli function vitro assay measur secret
ifn biomark t-cell activ show activ presenc antigen
figur cell yield rel electropor ep control
figur ifni releas post co-cultur
base strength preclin data initi develop allogen car-t
product target pediatr t-cell acut lymphoblast leukemia t-all pediatr acut
myeloid leukemia aml two underserv oncolog market enabl favor
competit regulatori dynam candid addit insert receiv
four simultan edit address key limit current allogen car-t therapi
prevent gvhd achiev edit tcr gene essenti
requir remov potenti gvhd transplant allogen car-
cell elicit immun respons attack patient healthi cell
enabl allogen cell sourc also import optim clinic benefit long-
term car-t cell persist patient immun system recogn
induc immun respons transplant car-t cell loss-of-funct
edit compon mhc class molecul would effect cloak car-t
cell recogn host immun system disrupt
gene would allow mab-medi condit use car-t
transplant facilit car-t engraft elimin wt alloreact
cell util approach clinic valid ph studi
minim interfer tumor microenviron tme immunosuppress
natur tumor microenviron play signific role diminish car-t
host immun cell activ persist acceler t-cell exhaust
effort augment car-t activ suppress surfac inhibitori marker
activ develop fact huge clinic success checkpoint
immunosuppression-disrupt edit investig disrupt surfac
express car-t cell potenti immunosuppress target base edit
disrupt includ fa
mab keytruda
prevent fratricid order prevent fratricid recognit destruct
one car-t cell anoth import elimin antigen share
malign cell car-t cell note especi relev
t-cell program fratricid problem target cancer cell
origin cell therapi potenti target cbe-medi disrupt includ
see particular rational ko given high
express level t-all normal express cell small subpopul
 cell call cell
figur potenti gene target amen multiplex base edit
addit describ edit also final stage select specif
antigen incorpor cell product combin multiplex edit
pair follow complet process plan conduct vivo studi
appropri anim model support ind file addit preclin car-t data anticip
versatil beam multiplex base edit platform enabl rapid expans
addit product candid particular abil perform multipl simultan
allow move difficult-to-treat solid tumor would requir increas number
edit overcom uniqu challeng tumor microenviron initi
hematolog malign product candid also potenti move
hematolog cancer share tumor-associ antigen
beam earlier-stag pipelin encompass non-vir deliveri via lipid nano-particl lnp
base edit candid liver diseas initi antitrypsin defici aatd
glycogen storag diseas type well aav-medi deliveri base edit
candid ocular disord initi inherit retin disord ird stargardt
diseas ind submiss program like although preclin updat
expect
non-vir base edit deliveri liver diseas
aatd sever inherit genet disord result mutat gene
normal encod antitrypsin protein patient phenotyp
vari depend type mutat whether defici absent dysfunct
common form aatd result point mutat inherit
autosom co-domin transmiss caus substitut lysin glutam acid
hing region protein mutat result increas tendenc
polymer aggreg toxic build-up within liver cell low level
circul approxim patient us sever form
two copi allel patient low circul lead lung tissu
damag neutrophil elastas build-up misfold caus inflamm cirrhosi
liver requir organ transplant
current treatment option diseas limit includ weekli iv augment
therapi slow diseas progress cure diseas stringent
adher therapi also critic therapi also limit avail high cost
burden per year furthermor gene therapi develop aatd
diseas requir high level protein express therapeut effect difficult
achiev aav approach also make sensit declin persist
time protein replac alon would expect address build-up
misfold liver would expect address liver diseas
knockout rnai gene edit liver part may amelior liver toxic would
also like lower circul level therefor exacerb progress lung
compon diseas
beam approach beam base edit approach uniqu posit address aatd
caus mutat abe precis revert point mutat
back correct base therebi allow product normal wt importantli
edit would simultan address lung liver compon
diseas restor secret remov build-up toxic protein
furthermor toxic mutant correctli edit cell
surviv benefit non-edit cell therefor would expect compris
greater proport total liver cell time show strength
discoveri effort develop novel base editor six month
capabl correct mutat human cell effici vitro
figur plan deliv base edit machineri aatd
liver diseas lnp deliveri well-valid deliveri mechan liver diseas
given particl natur affin uptak organ
step current conduct preclin studi confirm abil
correct sequenc exist enhanc mous model aatd also
optim lnp formul use mice nhp formul
encapsul mrna code base editor grna
use preclin updat program includ lnp deliveri data expect
figur aatd increas effici across abe variant month evolut
inborn disord glucos metabol caus autosom recess mutat
gene code protein defici
activ result liver inabl releas glucos glycogen caus
hypoglycemia low blood glucos level fatal pt adher strict regimen
slow-releas form glucos like cornstarch need administ everi sever hour
includ overnight inabl releas glucos also result build-up glycogen
liver kidney caus function impair organ case
hepatocellular adenoma carcinoma pt rare incid
live birth type current disease-modifi therapi avail
although aav gene therapi develop uncertainti durabl
transgen express key concern clinic crucial therapi consist
maintain glucos control long period time sleep night
approach approach lnp-deliv abe-correct
two preval mutat caus diseas point mutat
compris patient patient
us respect identifi product candid achiev edit
effici allel harbor mutat
cell harbor mutat figur importantli anim studi suggest
littl normal activ liver consid clinic meaning
allow suffici restor fast glucos
step like aatd current conduct studi confirm abil
precis correct mutat transgen mice harbor specif
mutat addit optim lnp formul use similarli
encapsul mrna code base editor specif grna preclin updat
program expect
figur abe correct preval disease-caus mutat
viral deliveri ocular disord
stargardt diseas inherit retin disord ird progress degener
macula eye result increas vision loss start adolesc ultim
lead central night vision blind common form stargardt result
autosom recess mutat gene respons encod protein
normal clear away toxic vitamin byproduct insid photoreceptor stargardt howev
protein dysfunct absent accumul toxic byproduct caus retin
cell destruct current approv disease-modifi treatment stargardt
diseas compani pursu aav approach allow product function
protein approach made difficult larg size gene
packag singl aav vector
beam approach beam base edit platform well-suit address stargardt
diseas given preval mutat caus diseas
point mutat could correct abe preval also common
insofar ird concern pt us affect mutat
furthermor diseas model use tini spot stimuli suggest diseas correct
could achiev edit effici advantag approach
direct correct allow gene benefit normal endogen regul
ensur appropri protein level produc rather risk product
sub-optimal supranorm protein express aav deliv exogen
product identifi base editor capabl edit approxim
allel recombin cell carri human mutat sequenc figur
deliveri consider develop aav deliveri approach base
editor ocular disord unlik electropor ex vivo program
scd/tdt car-t lnp deliveri vivo liver diseas program aatd
believ ration approach one local deliveri aav well-
valid system ird proven approv luxturna
encourag clinic data shown nightstar led acquisit
meiragtx nc appli genet agtc outperform other
eye immune-privileg given compartment easili access
direct precis inject whether intravitr subretin also lnp show
natur tropism eye liver electropor suitabl
ex vivo approach howev given beam base editor larger
packag capac singl aav need use split aav system deliv
base editor via two aav vector deliv two halv editor
recombin creat function base editor note split aav
approach necessit addit engin step make optim edit
difficult achiev nevertheless shown achiev edit
surrog base posit immedi adjac target base human retin
pigment epitheli cell line target would present stargardt-affect cell
figur also repres exampl potenti bystand edit would
silent result chang express amino acid synonym chang
deliveri base editor section discuss split base-editor dual
step current test aav split editor nhp studi
deliv via sub-retin inject mimic anticip rout administr
clinic also evalu retinal-specif promotor test express
editor retina minim express organ case leakag
although would unlik anyway given immun privileg natur eye
also plan soon test editor effici human retin organoid well
explor develop base edit candid address commonli
occur point mutat stargardt diseas anticip report preclin
nhp data aav deliveri approach base edit sometim
expans opportun addit explor addit stargardt-rel mutat
intend explor addit ocular diseas may amen aav-
deliv base edit also intend develop aav base editor deliveri
futur indic plan target clinic studi shown aav capsid
target tissu high degre tropism respect base edit
see differenti rel gene edit approach given
edit non-divid cell neuron cell gener significantli
figur stargardt diseas abe correct mutat cell
figur stargardt abe edit surrog base split aav deliveri retin cell
intellectu properti
beam competit advantag long-term valu proposit stem broad ip
portfolio encompass multipl dimens base edit platform decemb
own approxim pend us provision patent applic
pend intern patent applic would expect expir
exclud patent term adjust extens ip portfolio cover
aspect base edit platform includ around base editor
applic variou method system around evalu increas specif
compon deliveri modal
enter number licens agreement strengthen ip posit
platform option includ licens agreement harvard dna base edit ip
broad institut rna base edit ip edita medicin crispr-rel ip
biopalett base edit relat certain therapeut area
compani data decemb
licens overviewplatformapplicationscopeharvard univers edita medicineorigin abe cbe base editor dna base editingexclus right rescu c-to-u editorrepair a-to-i editorrna base edit human therapeuticsexclus right editingexclus right wholly-ownednew optim editor associ guid rna enhanc exist system develop new system exclus right use specif indic scd beta-th aatd stargardt other exclus right biopalettebas edit certain patent right relat treatment human diseas exclus ww right except microbiom applic asia edita editinglicens option right use broad institut via subsidiari blink
compani data decemb
overal anticip total royalti beam product candid high single-digit
rang may somewhat higher lower depend extent ip
incorpor product would higher incorpor edita
uc berkeley/broad institut ip disput eventu settl royalti paid could somewhat
higher uc berkeley eventu winner
research collabor agreement
also collabor agreement out-licens base edit tech
cardiovascular diseas recent prime medicin in-licens prime edit ip
specif indic applic
verv verv recently-launch privat biotechnolog
compani seri may focus gene edit strategi
modifi gene associ increas risk cardiovascular diseas april
enter collabor licens agreement verv
grant compani exclus licens certain base editor deliveri technolog
human therapeut applic cardiovascular target part
agreement verv conduct fund develop complet ph
studi may opt-in associ fee us profit-shar
product candid collabor target verv also grant equiti
prime medicin prime medicin recently-launch privat biotechnolog compani
built upon foundat work david liu harvard univers broad
institut prime edit next-gener gene edit technolog that
describ search-and-replac mechan septemb
enter collabor licens agreement prime medicin privat
exclus right prime medicin edit technolog prime edit specif
indic applic treatment scd correct single-
base transit mutat exchang non-exclus licens certain beam
crispr deliveri technolog includ must make reason effort
applic patent overviewexpirydna base editingin-licens us patent pend us patent applic pend pct applic base edit in-licens pend us patent applic pend pct applic pend ex-u patent applic pend us patent applic pend pct applic pend ex-u patent applic platformin-licens us patent pend us patent applic pend pct applic ex-u patent pend ex-u patent applic
develop seek regulatori approv least two product candid
incorpor prime technolog prime option co-develop
commerci certain beam-advanc product prime technolog us
addit prime owe potenti clinic regulatori commerci mileston
product candid collabor aggreg low-to-mid eight figur per
product royalti net sale also small equiti swap
part agreement oblig issu common stock prime
prime oblig issu share common stock
collabor extend beyond one year also provid manag serv
prime one year right design one member prime board
prime edit detail search-and-replac genom edit without double-strand break
prime edit gene edit method directli write new genet inform specifi
target dna site describ search-and-replac mechan prime editor
incorpor catalyt impair endonucleas fuse make single-strand cut
engin revers transcriptas domain encod desir edit guid rna
specifi target site provid rt templat desir edit see david liu semin
natur paper anzalon et al note prime edit demonstr capabl
perform target insert delet well address type point mutat
multipl cell line without requir dsb use donor dna templat capabl
describ search-and-replac gene edit could theoret address
known genet variant associ human diseas
mechan detail prime editor pe complex three primari function
domain nickas domain revers transcriptas domain prime edit
guid rna domain pegrna like gene edit modal guid rna confer
target dna specif case also contain new genet inform
replac target dna also like base editor endonucleas catalyt
impair cut singl strand dna confer nickas function
therefor similarli creat dsb make desir edit first pegrna bind
desir target dna sequenc nickas domain nick pam-
contain strand result end hybrid primer bind site pb
pegrna abl prime revers transcript via rt domain new
dna contain desir edit use rt templat pegrna creat
single-strand flap contain desir edit natur cellular process
flap equilibr flap cleavag ligat subsequ dna repaira stabl
edit dna sequenc form see figur
potenti advantag base edit base edit effici instal four
transit point mutat ct ga ag tc without requir dsb
format unlik prime edit unabl perform eight transvers point
mutat ca cg gt ac ta tg consequ limit
scope genet diseas modal address furthermor prime edit may
better suit transit point mutat target base well-posit
base edit pam sequenc exist within base pair
target site bystand base nearbi would undesir
edit off-target activ also lower prime edit lowest
among gene edit modal specif requir three level perform
edittarget dna-pegrna spacer complementar bind target dna-
pegrna-pb complementar initi pegrna-templ revers transcript
target dna-rt product complementar flap resolut contrast
specif mostli base target dna-guid rna complementar overal prime
edit offer greatest target flexibl precis among known gene edit
potenti drawback consider primari drawback
consider prime edit relat infanc technolog initi
proof-of-concept studi publish octob perform four
differ human cell line hela cell mous cell line
post-mitot primari cortic neuron given prime edit effici vari across
cell line test much unknown regard cell-typ cell-stat
determin prime edit outcom address edit strategi
perform may becom refin work conduct furthermor
liu lab gener insert bp delet bp clear
degre insert delet perform effici
off-target effect might impact prime editor also fairli bulki exceed
packag limit standard aav vector moreov respect base edit
particular experi also shown base edit superior prime edit
appropri posit transit point mutat base edit offer higher
edit effici fewer indel by-product format
signific short view emerg prime medicin
signific competit threat given infanc prime edit technolog
favor structur two compani collabor licens agreement
regard former recal base edit initi introduc
three year ahead prime edit given beam initi ind file anticip
first clinic prime edit candid may expect reach clinic
furthermor importantli structur beam collabor
licens agreement structur specif minim direct competit
two compani abl done due share scientif
founder david liu harvard univers broad institut share princip
investor base ventur partner part agreement prime grant
exclus licens use prime edit technolog transit point mutat
applic rememb gene edit found
collabor allow corner transit point mutat market
could util prime edit instanc base edit less applic
pam posit rel target base inappropri bystand edit
within activ window need minim addit agreement also grant
exclus licens use prime edit sickl cell diseas signific
competit reason given beam lead indic also
scd result singl transvers point mutat therefor could
complement initi two-prong approach scd transit point correct
makassar variant creation hereditari persist fetal hemoglobin
phenotyp direct transverion point correct natur hemoglobin
figur overview prime edit
known pathogen human genet variant clinvar access juli classifi type prime
edit complex consist pe protein contain rna-guid dna-nick domain nickas fuse
rt domain complex pegrna pepegrna complex enabl varieti precis dna edit wide rang
posit streptococcu pyogen pepegrna complex bind target dna nick pam-
contain strand result end hybrid primer bind site pb prime revers transcript new
dna contain desir edit use rt templat pegrna equilibr edit flap
unedit flap cellular flap cleavag ligat dna repair result stabli edit dna
current manufactur capabl intend use contract manufactur
organ cmo relev manufactur experi genet medicin
current partner one signific expertis manufactur guid rna
identifi addit cmo manufactur compon product
candid believ approach suffici cost-effect given early-stag natur
research program would anticip futur invest intern manufactur
capabl transit clinical-stag compani
gener face competit platform compani wide varieti compani
develop therapi genet diseas directli face direct competit
gene edit compani name crispr crsp cover intellia
neutral cover neutral
liana moussato precis bioscienc cover short although believ
beam base edit platform current best-in-class genom edit platform address
patholog character singl transit point mutat platform continu
evolv current capabl year show improv on-target specif
breadth address target decreas off-target effect
exampl case zfn edit recent technolog improv promis improv
on-target diminish off-target activ one studi off-target indel format shown
reduc maintain on-target effici engin folki
nucleas domain attenu activ miller et al anoth studi new linker
compon span finger-fing finger-foki cleavag domain junction develop
expand number avail zfn configur avail also
manner possibl multipl gene edit strategi may prove capabl advanc
competit clinic candid given diseas effect clinic outcom
function compar despit one product technic superior note proven true
currently-approv monoclon antibodi small molecul therefor weve
maintain gene therapi remain signific first mover advantag given
indic given intend cur natur therapi proper clinic execut
addit highlight environ rapid technolog advanc new genom
manipul technolog recent launch prime medicin notabl exampl
emerg competit platform although note prime structur
collabor dramat diminish posit competit threat
addit prime edit note earli emerg platform evolvr
crispr-associ transposas cast integr figur
nevertheless regard continu hold posit long-term outlook theyv
compil broad spectrum relev ip beyond abe cbe base edit mention
addit licens ip use prime edit transit point mutat scd
also capac develop gene edit candid incorpor technolog
rna edit allow stay ahead curv expand
versatil gene edit capabl
gene therapi expect face consider competit gene therapi
product candid recent advanc
transgen regulatori sequenc
optim vector engin deliveri dramat enhanc modal
feasibl abil function correct monogen diseas inde respect
beam pipelin expect strong gene therapi competit base edit
candid scd tdt stargardt diseas particular still despit
promis gene therapi strategi still larg limit mostli non-specif
transgen express therefor function cure genet
correct given genet condit gene therapi also challeng issu
durabl particularli aav potenti immunogen express product
time particularli modifi transgen potenti tumorigenesi case
lv-mediat insert mutagenesi although concern larg theoret
natur furthermor gene therapi remain limit address loss-of-
function mutat design disrupt pathogen mutat
prime edit prime medicin privat revers transcriptas fuse nickas pegrna guid gene insert delet replac broad search-and-replac function replac one target dna sequenc anoth current demonstr michigan cornel univers naturally-occur crrna-guid cascad target complex nuclease-helicas delet kb infecti diseas monogen diseas long repeat region dmd evolvrinnov genom institute/uc berkeley ucsferror-pron nick-transl dna polymeras fuse nickas continu mutagenesi direct evolut benefici phenotyp crispr-associ transposas cast integr harvard university/mit columbia universitynatur occur cascad genom associ transposaseslarg insert kb genet diseas requir insert larg genet sequenc ore insert larg transgen augment normal activ site-specif insert domain cell compani platformedit potenti applic edit construct
transgen express may prove less efficaci diseas dysfunct protein
still express
gene express regul advanc therapeut design modul
influenc express target protein without effect perman genet chang
also pose competit threat gene edit approach gener
approach includ applic gene silenc rna interfer rnai
use antisens oligonucleotid aso small interf rna sirna
short hairpin rna shrna compani pioneer approach alnylam
ioni arrowhead dicerna akcea ediso
experienc tremend growth recent year previou
limit therapeut util increasingli overcom advanc
drug deliveri approach involv deliveri mrna develop
compani bntx
also advanc consider recent year approach mani
aforement compani develop drug compet beam current
develop program although unlik gene therapi indirect competit
given differ risk-benefit profil therapi instanc rnai mrna
therapi intend chronic use one time deliveri direct
competit protein-bas biolog small molecul instead therapeut
also appreci expens chronic therapi except perhap
enzyme-replac therapi orphan drug specialti pharma drug
therefor may prove signific commerci competitor gene edit
protein-bas biolog small molecul even cell gene therapi increasingli
becom clinic valid expect protein-bas biolog small molecul
continu hold relev given diseas treatment paradigm factor
continu util includ cost patient physician prefer diseas
sever inher tunabl abil easili adjust dose discontinu
altogeth need furthermor case oncolog exampl continu
innov understand tumor microenviron may drive
develop tradit drug mimic function engin
enhanc cellular immunotherapi unlik emerg
checkpoint inhibitor quickli outpac therapeut util oncolyt virus
cancer vaccin nonetheless believ advanc gene edit capabl
deliveri along grow awar among stakehold increasingli address
limit cell gene therapi diseas program
initi target note protein-bas therapeut small molecul
meaning competit oncolog program lesser degre scd
figur select publicly-trad gene edit gene therapi landscap
thomson reuter close wedbush secur
companytickershar highytdshar equiv current evev/ sharemarket capgen edit companiescrispr edit adjac compani bluebird gene therapi genet gene express regul compani alnylam biotbio life edit compani median averag select relat compani median averag therapi compani median averag express regul compani median averag indic etf select sector sprdr fund biotech nasdaq biotechnolog fund perform genet medicin perform genet medicin compani
sickl cell diseas beta-thalassemia
scd tdt extrem crowd indic gene edit therapi approach given
clear genet basi substanti market size bio outperform gene
therapi candid lentiglobin repres nearest-term competit
current approv tdbt european union market zynteglo bla file
expect us also registr studi scd addit sever gene
edit compani pursu indic includ sangamo crispr
ph well preclin candid edita homolog
addit numer small molecul protein-bas therapeut develop
aim address manifest scd hemodynam improv ultim
find group compet agent less competit gene edit gene therapi
approach expect cur
preclin comparison gene edit candid scd
two primari scd strategi gene edit restor wt gene sequenc
homology-direct repair base edit activ fetal hemoglobin hbf
typic disrupt -globin repressor bind site promotor
-globin gene approach disrupt activ
investig benefit fact known function erythroid lineag
mediat fetal-to-adult globin switch
crispr/vertex crispr therapeut partner vertex advanc
gene edit candid target erythroid enhanc region
preclin data first present includ vitro allel
edit effici donor stem cell biallelec edit erythroid
differenti roughli vitro hbf protein level edit cell post-
differenti base data compani initi ph
trial recent report initi data studi first treat patient see
sangamo/sanofi sangamo partner sanofi employ zfn
platform disrupt target disrupt gataa motif
erythroid-specif enhanc region preclin data last present
show effici edit allel vitro hbf level vs
unedit cell vitro hbf cell frequenc vs unedit cell
determin flow cytometri base result sanofi launch ph trial
intellia/novarti intellia partner novarti also develop ex
vivo edit candid target erythroid enhanc region
preclin data report includ edit rate
healthi stem cell note effici across variou hspc subset
approxim vitro hbf protein level report edit cell
erythroid differenti vs unedit cell furthermor edit cell
transplant immunocompromis mice edit cell found constitut
bone marrow week hbf level observ
engraft hsc underw erythroid differenti vitro note earli
data encourag appear intellia novarti de-priorit
develop candid
overal group shown encourag effici disrupt remain
unclear whether disrupt erythroid enhanc may result undesir erythroid defect
human note data suggest undesir effect fact case
crsp report contradict data gener view direct edit
-globin gene regulatori sequenc superior approach
edita edita pursu gene edit approach scd
initi determin engin variant outperform variant
target distal ccaat box promot attribut greater
proport larger bp nhej-medi indel format superior gene disrupt
engin variant attain edit effici cell
vitro well vivo hbf level immunocompromis mice wk post-
transplan edit cell compani present note
data stack compar beam edit vivo hbf express level
respect turn appear superior edit perform
approach given find believ edit prove
competit strategi view strongest gene
edit competitor scd furthermor believ abe strategi
prove superior edit approach given lack gener dsb
limit off-target activ although note report discern off-target
edit target sequenc techniqu current
complet ind-en studi anticip submit ind
figur preclin edit data hemoglobinopathi candid
note edit effici taken healthi donor cell rather donor scd cell
fraction determin engraft hsc differenti vitro
compani data report wedbush secur
product candidatecompanyedit machinerygen target edit cell vitro hbf post-erythroid differenti vs unedit control vivo mous hbf fraction post-transpl edit cell wk vs unedit data candidatebeam abe base candidatebeam abe base
earli clinic benchmark scd -thalassemia genom edit
first clinic dataset gene edit candid hemoglobinopathi begin
matur initi data limit number patient recent report scd
tdbt tdbt dataset serv use earli benchmark
base edit candid enter clinic
data first patient treat climb-
studi beta-th scd respect first treat
patient total hb level g/dl baselin includ hbf subsequ
experienc improv hemoglobin fraction time point four-month
period total hb increas clinically-meaning g/dl
composit hbf pathogen hb notabl
improv hemoglobin translat meaning clinic benefit includ
voc sinc infus transfus first month patient
previous experienc averag voc episod per year final safeti profil
consist standard myeloabl busulfan condit hsct three
sae occur resolv deem relat figur
first treat patient genotyp baselin
transfus burden histori transfus per year also achiev clinic
meaning improv measur hemoglobin total hb increas
g/dl month g/dl baselin remain level throughout
nine-month period furthermor hbf level increas g/dl month
g/dl baselin continu increas g/dl total hb nine month
notabl patient requir addit transfus first month
start phlebotomi month restart iron chelat therapi month
scd safeti profil consist standard condit transplant
two sae occur resolv consid relat
overal view data encourag initi valid gene editing-medi hbf
re-activ albeit two pt de-risk similar approach other
crsp anticip present updat clinic data addit patient
program major medic meet like eha
compani also believ respect trial could demonstr compar efficaci
safeti achiev first two patient addit patient
current program may abl serv registr studi howev given
current preced zynteglo believ larger studi least scd
like necessari
ph data sangamo/sanofi preliminari data ph thale
studi three patient tdbt report short
patient exhibit increas hbf post-infus therebi valid activ zfn-
mediat fetal hemoglobin re-activ effect neither signific durabl
increas seemingli peak month decreas two three patient
figur although earli day ph program
sangamo crispr data five patient date like
prove competit candid go forward
figur initi ph data fetal hemoglobin g/dl time evalu patient
figur competit landscap gene cell therapi sickl cell diseas
compani data report clinicaltri gov wedbush secur
drugclasscompanydelivery/ dosestage/ studykey data develop notesgen cell therapi lentiglobingen therapi lv modifi transgen expressionbluebird bio ex vivo lentivir ph updat group pt w/ mo follow total hb rang g/dl g/dl subset pt w/ voc ac event yr prior treatment reduct voc ac event rate observ -last data updat complet date orphan medicin product design european commission-orphan drug stateu regen medicin advanc therapi design edit targetcrispr/vertex crsp/vrtx ex vivo electropor ph studi updat first pt enrol achiev neutrophil platelet engraft day post infus pt free voc month post infus hb level g/dl hbf f-cell -last data updat -primari complet date track edit zfn targetsangamo/sanofi sgmo/sni ex vivo electropor ph trial initi complet date therapi lv modifi transgen expressionaruv privat ex vivo lentivir ph trial updat scd pt one pt total hb anti-sickl w/ total hb month one voc pt total hb anti-sickl total hb month scd-relat voc episod chronic pain requir oral opioid -last data updat orphan drug design start date shrnagen edit shmir lv targetbluebird bio ex vivo lentivir tph trial updat pt monht follow hb level g/dl one pt sever underli neurovascular disseas transfus interv increas month exclus licens boston children hospital-last data updat start date comlet date therapi lv encod behringex vivo lentivir ph initi complet date edit targetedita ex vivo ribonucleoprotein-electroporationpreclin meet detectbl off-target edit -preclin data meeting-ind file date edit targetedigen privat ex vivo electropor preclin preclin manufactur data present programgen edit nv intellia ex edit preclin -arti complet ind-en studi potenti ind filinggen edit candid gene edit aav-medi homolog recombin nd targethomolog ex vivo like aav tpreclin
figur competit landscap small molecul biolog sickl cell diseas
compani data report clinicaltri gov wedbush secur
small molecul biolog rivipanselpan-selectin antagonistpf ivph meet primari key secondari efficaci endpoint ph reset trial crizanlizumabanti-p-selectin mabartisivph dose crizanlizumab vs placebo adolesc adult scd pt histori voc-studi start date primari complet date approv fda anti-p-selectinglob blood therapeut ivph healthi volunt complet roch feb compani websit manufactur underway-right acquir roch sodiumheparin derivativemodu therapeut privat ivph reduc voc event may formul decitabin tetrahydrouridineo nordiskoralph epidestini total deal valu includ milestones-ph trial hv complet may pediatr diseas orphan drug fast track inhibitorimara privat oralph toler ph studi healthi volunteers-ph studi initi complet expect track inducerfulcrum therapeuticsoralpreclin -ind submiss expect gamma globin gene expressionsyros/glob blood syrs/ oraldiscoveryidentifi target gene control platform-partnership initi dec present progam
figur competit landscap gene cell therapi beta-thalassemia
compani data report clinicaltri gov wedbush secur
drugclasscompanydelivery/ dosestage/ studykey data develop notesgen cell therapi lentiglobingen therapi lv modifi transgen expressionbluebird bio ex vivo lentivir hsct ph pt w/ follow transfus independ total hb median g/dl mo pt mo follow-up transfus independ mo median mo g/dl-approv eu zynteglo-last updat drug breakthrough therapi design therapi lv human beta globinorchard ortx ex vivo lentivir hsctph tiget-bth updat asgct month pediatr pt transfus independ adult pt transfus reduct trae report month follow-up -acquir gsk april ema prime edit zfn targetsangamo/sanofi sgmo/sni ex vivo electropor hsct ph thale interim updat first pt hbf concentr increas baselin indel persist peripher leukocyt month one sae hypersensit resolv end infus studi enrol patient -studi primari complet dec start date edit targetcrispr/vertex crsp/vrtx ex vivo electropor hsct ph studi updat first patient genotyp achiev neutrophil engraft day platelet engraft day post infus pt transfus indepent month post infus hb level hbf f-cells-studi start date primari complet track design edit targetedita ex vivo ribonucleoprotein-electroporationpreclin meet detectbl off-target edit -preclin data meeting-ind file date gene edit therapypeptid nucleic acid pna editingtrucod gene repairpreclin
figur competit landscap small molecul biolog beta-thalassemia
compani data report clinicaltri gov wedbush secur
drugclasscompanydelivery/ dosestage/ studykey data develop notessmal molecul biolog mimeticprotagonist therapeuticss ph trancendpreliminari result ph trancend trial statist signific reduct baselin serum iron transferrin satur mg mg weekli doses-last data updat efficaci result expect inducerrar partnersoralph start data expect inhibitorvifor pharmaoralph trial show adequ inducerfulcrum therapeuticsoralpreclin -ind submiss expect inhibitorimara incoralph ph studi beta thalassemia slate start preliminari data disclos compani filing-a ph studi complet beta thalassemia formul decitabin tetrahydrouridinenovo nordiskoralph epidestini total deal valu includ milestones-ph trial hv complet may pediatr diseas orphan drug fast track galnac sirna conjugatesil therapeuticss ph model show inhibit modul iron level vivo sever wek non-transfus depend ph trial initi estim primari complet inhibitorvifor pharmaoralph poc trial expect begin ph studi adequ antisens drugioni pharma ph studi hv complet depend ph studi expect start gamma globin gene expressionsyros/glob blood syrs/gbt oraldiscoveryidentifi target gene control platform-partnership initi dec present progam
edit car-t space also area fierc competit face competit
pure-play cell therapi compani larg pharmaceut virtual pertin gene
edit compani includ allogen cellectiss talen-edit allogen cell therapi
among gene edit compani crsp advanc wholly-own edit car-t
disclos antigen bcma hematolog malign
current ph also wholly-own car-t call
clinic along preclin program target bcma cll mm
aml respect addit advanc wholly-own tcr-t cell candid aml
target preclin studi collabor gilead via kite
variou cell therapi although candid compar earlier preclin stage
final number partnership cellular immunotherapi space includ car-
cell bristol-my squibb via juno engin ipsc nk cell therapeut
allogen nk cell non- cell therapi sandhil therapeut well
intern edit cell therapi program competitor dtil aml program
repres direct competit beam initi allogen aml program edit gene
edit ipsc nk t-cell program like repres signific gener platform
competit beyond gene edit also note competit allogen cell
therapi cll among other see strongest
competitor platform perspect use induced-pluripot stem cell ipsc versu
cllss donor-edit cell
note tabl includ engin nk-cell landscap note addit competit therapi nk
compani data report clinicaltri gov depil et al wedbush secur
compani candidatecel type/ sourceallogen modificationsgen edit tool antigen modificationsphas trial indicationsaddit commentarybeam multiplex edit donor cell undisclos multiplex editscb base edit ndndpreclinicalt-allaml-fin select domain multiplex edit cell trac servier cell cell talenbcma ph cell cell cell cell talennd preclinicalndatara ebv-t cell ebv-specif cell line retrovir co-stimulatori domainpreclinicalb-cel cell trac bpdcn-first patient dose jan cell trac patient dose dec cell trac approv jan cell trac kotalen insert cell express tim trac inhibit molecul peptid consist truncat vector co-express trac-inhibitori molecul data updat orr -ph expans cell nondisclos cell nondisclos cell nondisclos cell trac cancers-ent clinic jul cell trac jan cell trac tumor edita medicin healthi donor nk ipsc nk cell cellmultiplex edit preclinicalmultiplemultipl collabor -sandhil binat tech better donor extract expansion-bluerock ipsc platform -bristol-my hold option t-cellsintern program right non- cell cell trac insert trac co-stimulatori domainpreclinicalb-cel cancersind submiss ip gene edit ipsc-deriv cell therapeut use memori sloan ketter expand may memori t-cell enrich cellstrac mhc class kocrispr-dead fuse nucleas bcmasafeti switchpreclinicalmm-ind file expect cell trac koarcu meganuclseas insert trac co-stimulatori domainph nhl-partner servier-initi data orr correl demonstr expans cell trac dose cell trac koarcusbcma ph dose cell knockdownshrna preclin -stealth -t expressionsangamo cell trac w/ w/o cish kozfn insert tracpreclinicalb-cel cancers-ph initi gilead kite privat -transduc cellsdonor cell t-cell depletioncel sortingnd ebv-t cell ebv-specif cell line lymphomatri run baylor shrna tech licens horizon discoverycelyad cyad cellecti cll precis bioscienc crsp
overal competit landscap aatd crowd like function
difficulti diseas target direct gene edit competit come primarili intellia
develop vivo lnp-deliv gene edit candid current preclin studi
although compani recent de-priorit develop favor hereditari
angioedema edita whose gene edit candid also preclin stage believ
may show superior candid superior edit effici
predict respect gene therapi approach develop believ
particularli difficult succeed aatd diseas requir high level protein express
therapeut effect make sensit declin persist time
would expect address build-up toxic misfold liver therefor
would expect address liver manifest diseas recent
valid adverum cover discontinu aav gene therapi candid
unabl produc express suffici level protein beyond gene
edit therapi rnai therapi also develop alnylam cover aln-
enter ph trial data expect arrowhead
cover rnai candid aro-aat enter potenti pivot ph
trial ph data includ maximum serum knockdown mean
knockdown four treat patient moreov rnai therapi repres nearest
term competit rational approach may amelior liver toxic
also expect approach meaning address lung compon diseas
would also like lower circul level final small molecul approach
develop assist partial restor secret fold approach
would requir chronic dose yet clinic character
littl competit stargardt diseas despit compar high
preval ird total pt know nightstar develop gene
therapi stargardt earli preclin develop time
neutral laura acquisit compani awar priorit
program relat program clinic develop mostli ist focus
investig subretin inject donor stem cell gener believ gene therapi
approach offer superior stem cell transplant given expect greater product
function protein see preclin program notabl competit
howev note stargardt ideal therapeut target ird given
gene packag singl aav vector due larg size beyond gene
cell therapi alkeu pharma privat develop small molecul drug design
prevent format toxic vitamin dimer eye current ph studi
estim primari complet date
compani data report clinicaltri gov wedbush secur
drugclasscompanydelivery/ dosestage/ studykey datanotesd base edit candid gene edit abe base edit correct mutationsbeam ivpreclinicalachiev edit effici mutat therapi dual function aav-basedap inc privat ivpreclinicalin mous model dual function vector use mirna target simultan drive express mirna-resist wt -pim-sil defect gene replac w/ normal gene-spin-off univers massachusett medic candidategen therapi therapi via lnp aav consecut esgct meet achiev reduct piz sustain therapeut level durat studi mous model-develop timelin therapi oxid resist hu variant via aavlexeo privat ivpreclin substitut and/or oxidation-resist variant hu award nih rant expect within year therapi aav-basedlog ivpreclin base proprietari generid platformd candidatenanoparticl deliverytrucod gene therapi agtc agtc ivdiscontinuedph reult higher dose level vg/kg mean serum express level um day um day um therapeut threshold serum therapi show meaning protein express ph advanc studi target ph studi nhv show aro- well toler differ placeo chang studi visit-ph sequoia trial start aug complet may open-label studi start dec prmari complet extens studi offer pt elect continue-receiv track design molecul correctorvertex pharmaceut oralph studi start date jan updat expect complet date target ph ph trial earlier gener candid aln- termin due elevatedliv enzym subset pts-studi start date dec complet date june target ph data piz mice monkey show dose effect protein knockdown-began enrol hv ph estrella studi dose pt ph studi molecul correctorvertex pharmaceut inc oralph studi healthi volunt on-going pr human fc fusion proteininhibrx inc inbx ivph ph studi first pt dose pk data dose escal portion expect complet date may candidatesmal molecul discoveri center gmbh privat oraldiscoveri receiv euro fund project partnership mcgill univers inserm semmelwei candidatesmal molecul chaperonez factor ltd privat oraldiscoveri receiv pound plan enter clinic lead candidatesmal molecul logicsgen therapi
compani data report clinicaltri gov wedbush securiti
drugclasscompanydelivery/ dosestage/studykey datanotesgen edit therapi candidatesstargardt diseas candidatebas edit split-intein dual aav deliveri abe editor mutationbeam therapeut like subretin injectionpreclinical-earli preclin data show edit allel recombin mutat cells-preclin updat expect diseas candidategen therapi dual aav deliveri split protein appli genet agtc subretin injectionpreclinicalsuccess express full-length nhp model local subretin bleb-announc compani second preclin program therapi dual aav deliveri protein gen subretin injectionpreclinicalpreclin ko mous model suggest express local function protein -program obtain via acquisit nite in-licens univers oxford therapi aav minigen therapyiver inc ise like subretin injectionpreclinicalprogram collabor umass medic school-preclin result expect therapi lentivector deliveri gene sanofi sa sni subretin injectionph discontinu repriorit oligonucleotid inhibit exon skip pre-mrnaproqr therapeut bv prqr like ivtpreclinicalantisens oligonucleotid aon identifi correct vitro-pat submit observ long retin half-lif requir less frequent dose stargardt diseas candidateantisens oligonucleotid stereopur life scienc ltd ivtpreclinicalcompani achiev knockdown target rna retina month platform-compani evalu multipl retin diseas name usher syndrom type first develop candid therapi deliveri retin pigment epithelium cellsastella pharma injectionph small molecul protein-bas therapeuticsemixustatsmal molecul inhibitoracucela privat /kubota pharmaceut hold pt enrol jan enrol target enrol complet date start date drug designation-ph studi ga fail meet primari endpointzimuralog aptameriver inc ise ivtph pts-toplin data expect start date molecul acet vita replac alkeu pharmaceut inc privat oralph ph studi healthi volunt complet studi estim enrol complet dec start date soraprazan acid pump antagonistkatairo gmbh privat oralph first patient ph startt studi treat june target enrol schedul studi complet molecul inhibitorstargaz pharmaceut privat oralph date pt enrol enrol hv molecul inhibitorbelit inc privat oralph healthi volunt complet sept drug design eu molecul zeaxanthin cardax inc privat oralpreclinicalearli gener drug shown protect rpe cell oxid stress
competit come name ultragenyx outperform laura chico aav gene
therapi candid current ph studi demonstr initi clinic
efficaci patient show improv time hypoglycemia first two dose level
studi ultim howev see potenti advantag beam base edit approach
allow endogen regul wild-typ enzym importantli would expect
face durabl concern major patient pediatr durabl
aav would expect wane time aav-medi express diminish
success cell divis beyond notabl comp includ
cover mrna candid crsp gene edit candid
preclin develop see disadvantag mrna approach given would requir
chronic treatment versu one-tim cure believ beam superior edit platform
give nod crspr approach
compani data report clinicaltri gov wedbush secur
drugclasscompanydelivery/dosestage/studykey specif base editingbas edit mutationbeam vivo lnp deliveri preclinicalachiev edit effici allel harbor mutat specif base edit base edit mutationbeam vivo lnp deliveri preclinicalachiev edit effici allel harbor mutat gene therapi express iv infusionph first cohort pt respond increas time hypoglycemia cornstarch intak reduct trsae expans cohort data expect potenti ph trial start start date primari complet date nucleic acid ena splice correctiondaiichi mrna encod enzym ivpreclinicala preclin mous model show dose-depend improv fast glycemiaand serum triglycerid reduct -compani current plan ph dose escal studi
market opportun valuat
gener difficult assess long-term commerci prospect beam lead product
candid given early-stag natur ind file expect
uncertain develop timelin competit profil nevertheless initi assign
valu seven beam name diseas program despit preclin stage believ
beam novel base edit platform potenti rapidli gener best-in-class product
candid cur potenti rare genet diseas character singl transit point
mutat well develop competit allogen car-t therapi highli versatil
function gener assumpt beam valu product candid includ
fda-approv lead product candid begin anticip
submit initi wave ind anticip roughli year
activ develop gain approv note number
factor could influenc timelin quicker slower time clinic
better- worse-than-expect clinic profil chang regulatori environ
view assumpt larg in-lin develop expect gene
therapi roughli follow-up meaning size patient cohort
suffici approv respect car-t candid cancer gener see
quicker path market rel rare diseas pathway particularli pediatr
time peak market penetr span year expect take
time attain peak market penetr base edit candid
although note often seen new class therapi howev
see potenti upsid launch ramp stakehold awar around cell
gene therapi like grown consider time beam candid
abil command premium price believ one-tim potenti cur
treatment indic pursu justifi premium price power
current model price rang total cost per patient
believ reason given degre uncertainti regard exactli durabl
gene edit candid prove assign least multipl annual
treatment cost diseas adjust accordingli exist approv comp
model zynteglo price beam scd tdbt candid regard view
price within framework gene therapi assum five-year value-
base payment time price model non-oncolog base edit candid
payment model current model total cost therapi paid
equal annual instal five-year period discount outcome-
base valu adjust reflect certain percentag patient may
fulli respond meet outcom requir
commerci adopt us eu current model commerci adopt
beam base edit candid us eu market
clearer regulatori path approv amen premium price
feasibl compani beam statur go market market
also robust infrastructur genet test may prove especi
valuabl certain monogen diseas stargardt exampl
high risk-adjust discount rate product given candid
preclin stage novelti edit platform initi assign high-
risk adjust discount rate product reflect each develop uncertainti
moreov note sinc market assumpt unadjust sale outlook
assum best- second-in-class diseas program program valuat
highli sensit discount rate exampl note candid
receiv ind clearanc enter ph studi could warrant drop discount rate
pt would increas manner reflect
long-term posit view compani expect rapidli appreci
valu transit clinical-stag compani
market opportun sickl cell diseas beta-thalassemia
overal assign total valuat beam hemoglobinopathi program
scd beta-th respect develop two separ scd
diseas program parallel current incorpor candid singular outlook
beam commerci outlook indic note highlight potenti approv
gene therapi zynteglo gene edit candid ahead beam
candid potenti approv like cannib degre exist scd preval
popul current model peak penetr popul
howev respect incid popul model peak penetr reflect
candid best-in-class potenti addit although substanti competit
scd beta-th market also signific genet diseas expect
surpass ww sale
prevalenceincidenceprevalenceincidenceprevalenceincidencepopul assumptionstreat opportun per penetr increas patient per year treat per assumptionspric per instal valu price increas assumptionslaunch date penetr decreas penetr penetr rate per eu row sickl cell diseas scd
figur ww brand hemoglobinopathi market expect grow annual
note model drug consensu estim avail endari notic absent therefor
estim like underestim growth potenti hemoglobinopahti market reblozyl estim
beta-th
evalu pharma consensu estim wedbush secur
prevalenceincidenceprevalenceincidenceprevalenceincidencepopul assumptionstreat opportun per penetr increas patient per year treat per assumptionspric per instal valu price increas assumptionslaunch date penetr decreas penetr penetr rate per eu row transfusion-depend beta-thalassemia tdbt
market opportun pediatr t-all aml
overal assign total valuat per share beam pediatr t-all aml
program program beam car-t program constitut
valuat compani mostli consequ diseas rel small
address market newly-diagnos patient year us eu addit
view program strateg entri car-t space face consider
less competit rel compet allogen therapi adult hematolog malign
b-cell malign furthermor expect eventu move solid tumor
substanti larger address market establish proof-of-concept
diseas see signific upsid potenti car-t platform
us eu row popul assumptionstreat opportun per penetr increas patient per year treat per assumptionspric per price increas assumptionslaunch date penetr decreas penetr penetr rate per t-cell multiplex-edit car-t cell us eu row popul assumptionstreat opportun per penetr increas patient per year treat per assumptionspric per price increas assumptionslaunch date penetr decreas penetr penetr rate per car-t cell pediatr aml
overal assign total valuat per share beam aatd program indic
compris half valuat larg consequ
substanti address market patient amen mutat lack competit
current develop still despit lack competit assum peak penetr
preval popul anticip physician patient prefer
support therapi mani patient may far advanc elig correct
prevalenceincidenceprevalenceincidenceprevalenceincidencepopul assumptionstreat opportun per penetr increas patient per year treat per assumptionspric per instal valu price increas assumptionslaunch date penetr decreas penetr penetr rate per eu row antitrypsin defici aatd
overal assign valuat per share beam program consequ
rariti genet diseas well potenti competit compet gene therapi
overal assign valuat per share beam stargardt program
consequ smaller number address patient amen mutat well
potenti competit gene therapi approach agtc biib gene therapi
prevalenceincidenceprevalenceincidenceprevalenceincidencepopul assumptionstreat opportun per penetr increas patient per year treat per assumptionspric per instal valu price increas assumptionslaunch date penetr decreas penetr penetr rate per eu row glycogen storag disord type prevalenceincidenceprevalenceincidenceprevalenceincidencepopul assumptionstreat opportun per penetr increas patient per year treat per assumptionspric per instal valu price increas assumptionslaunch date penetr decreas penetr penetr rate per eu row stargardt diseas
platform compani believ number addit lever upsid
could continu drive compani long-term valu first believ posit
benefit licens collabor activ industri partner would provid
meaning sourc non-dilut revenu potenti mileston payment royalti
regard state anticip retain wholly-own econom
mani program possibl therebi prematur sell right might evolv
competit program seen gene edit peer still see
rational structur collabor around non-cor therapeut area
maxim platform econom potenti addit note
current pursu develop us eu see expans addit
territori japan greater china busi develop activ meaning
sourc non-dilut revenu potenti royalti final may also gener addit
valu intern advanc strateg partnership addit edit
technolog prime edit rna edit edit
follow recent initi public offer rais gross proce expect
finish cash equival posit roughli furthermor
expect quarterli cash burn around believ
compani well-fund runway
initi coverag outperform rate price target pt deriv
sum-of-part valuat compani seven preclin diseas program
pediatr t-all aml scd tdbt aatd stargardt diseas program
appli multipl us/eu estim sale less high single-digit royalti per program
valuat year discount back risk-adjust discount rate
expand valuat tabl figur
salesvaluationincidenceprevalenceinc prev yearrat mm mm car-t oncolog pipelineu diseas pipelin us estim antitrypsin defici aatd scd-candid tdbt-candid aatd-candid sickl cell diseas scd launch datep shareclin programindicationmarketaddress ptspeak penetrationsalesmultipleeconomicsexpect price/ptaml-cart pediatr t-cell pediatr aml acronym definit acut lymphoblast leukemia aml acut myeloid leukemia methodolog note car-t product candid sum-of-part valuat base industry-standard multipl valuat year product sale discount back annual risk-adjust discount rate non-oncolog product candid appli methodolog target indic incid popul npv sale target indic preval popul util risk-adjust discount rate therefor sale multipl valuat year tabl relat incid popul valuat metric relat incid preval popul price/pt launch date econom discount rate peak sale valuat per share valu sale estim probability-unadjust stargardt-candid stargardt diseas glycogen storag disord type transfusion-depend beta-thalassemia tdbt
wedbush secur estim compani report
product expens oper incom interest incom non-op incom incom incom incom ep share dilut share thousand except per share data
figur fda-approv therapi hemoglobinopathi
compani data report fda packag insert wedbush secur
mechanismadministrationapprovallabelannu approvalsdevelop noteskey data/approv basissafety/oth commentarysickl cell diseas oxbrytavoxelotorglob blood therapeut small molecul sickl hemoglobin polymer inhibitoror mg dose adult children confirmatori studi underway includ children yo studi pt mg dose increas hb baselin g/dl reduct indirect bilirubin reduct precent reticulocyt count statist signific placebo week pt receiv bakground hydroxyurea therapi common incid headach diarrhea abdomin pain nausea fatigu rash pyrexiaadakveocrizanlizumabnovarti nv mab anti-p-selectin iv mg/kg minut wk wk everi wk pt regular approvalsustain studi pt studi drug lower annual rate voc event annual rate day hospit compar pbo control annual rate voc annual rate day pt studi drug experi voc placebo group common incid nausea artralgia back pain pyrexiaendaril-glutamineemmau life scienc privat small molecul mechan fulli understoodor pt fast track develo fda odac panel vote approv adult childrenph studi period endari pshad reduct averag cumul crisi count placebo group common incid constip nausea headach abdomin pain cough pain extrem back pai chest painbeta-thalassemia reblozylluspaterceptbristol myer fusion protein activin receptor type iia ligand trapsc mg/kg anemia beta-th per vial none-also develop mds-relat anemia believ studi proport treat pt achiev least reduct total transfus -- vs placebomost common incid headach bone pain arthralgia fatigu cough gi symptom dizziness-warn precaut hypertens thrombo-embol event zynteglo lentiglobinbluebird bio ex vivo lv transduct modifi yr none current approv european union-assess ema prime progam-condit market authorizatoinph studi pt achiev transfus independ ti ti maintain month on-going studi pt avheiv ti respond maintain ti monthscommon advers reaction thrombocytopenia hot flush dyspnoea abdomin pain pain extrem non-cariac chest paintrad namegener namecompanydrug infodevelop note data
mr evan helm ceo sinc april prior join mr evan
ventur partner ventur partner mr evan also serv svp corpor
develop portfolio leadership agio pharmaceut director product
develop infin pharmaceut mr evan also spent time mckinsey compani
busi analyst senior associ medimmun summer associ corpor
develop mr evan ba english yale univers
univers pennsylvania healthcar manag wharton school
giusepp ciaramella ph presid chief scientif offic
dr ciaramella join feb presid cso join mr ciaramella
csa valera compani dr ciaramella also held role vice-president head
immunolog execut director extern project infect
astrazeneca founder director ciaramella consult vice-president head collabor
research boehring ingleheim dr ciaramella also work nearli decad
held multipl role last posit execut director head dr
ciaramella receiv sc ph biochemistri univers colleg london
ms burrel join august compani cfo spent decad
morgan prior held role manag director vice presid ms burrel
also work equiti research associ hold bachelor degre harvard
univers new york univers leonard stern school busi
christin bellon ph svp chief legal offic
dr bellon brought april chief legal offic prior dr bellon
senior vice presid gener counsel also held previou role
svp legal affair vice-president legal affair blueprint medicin vice-president ip legal
affair hydra bioscienc assist gener counsel ip infin pharmaceut patent
counsel wyeth associ fish richardson dr bellon hold degre
chemistri yale univers ph organ chemistri massachusett institut
technolog law columbia law school
ms oconnor join aug head peopl organ
appoint may chief human resourc offic prior ms oconnor chief
peopl offic celsiu therapeut also work third ventur serv
interim human resourc execut ms oconnor also founder ceo oconnor
associ serv interim svp human resourc execut
relay fulcrum decibel voyag
blueprint medicin ms oconnor also held role vice-president human resourc world wide
director human resourc talent acquisit johnson johnson ms oconnor receiv
ba degre provid colleg
multipl us/eu sale lead preclin diseas program t-all aml scd tdbt aatd
discount rate appli
risk attain price rate
biggest near-term overal risk valuat price target poorer-than-expect preclin data beam base
edit platform particularli greater-than-anticip off-target activ unanticip safeti signal shown
would signific neg read-through compani product candid long-term risk includ worse-than-
expect clinic efficaci beam product candid greater-than-expect competit factor may advers
materi impact product candid market potenti valuat also polit regulatori commerci risk
unabl command favor reimburs adopt market product
david nierengarten jeffrey la rosa matthew barcu certifi view express report accur reflect
person opinion directli indirectli receiv compens payment connect
specif recommend view contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
march
march
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
